[4] Wiendels NJ et al. Chronic frequent headache in the general population: Comorbidity and quality of life. Cephalalgia. 2006;**26**:1443-1450

[5] Berra E et al. Cost of chronic and episodic migraine. A pilot study from tertiary headache centre northern Italy. The Journal of Headache and Pain. 2015; **16**:532

[6] Munakata J et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2009;**49**:498-508

[7] Magiorkinis E, Diamantis A, Mitsikostas DD, Androutsos G. Headaches in antiquity and during the early scientific era. Journal of Neurology. 2009;**256**:1215-1220

[8] Ad Hoc Committee on Classification of Headache. Classification of headache. JAMA. 1962;**179**:717-718

[9] Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;**8**:1-96 Society diagnostic criteria. Headache.

*DOI: http://dx.doi.org/10.5772/intechopen.93314*

headache in a population-based study.

Pathophysiology of migraine: A disorder of sensory processing. Physiological

[29] Schwedt TJ. Chronic migraine. BMJ. 2014;**348**:g1416. DOI: 10.1136/bmj.

[30] Goadsby PJ. Migraine, aura and cortical spreading depression: Why are we still talking about it? Annals of Neurology. 2001;**49**:4-6. [PubMed:

[31] McNaughton FL, Feindel WH. Innervation of intracranial structures: A

[32] Penfield W, McNaughton FL. Dural headache and the innervation of the dura mater. Archives of Neurology and

[33] Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Archives of

[34] Marfurt CF. The central projections of trigeminal primary afferent neurons

tranganglionic transport of horseradish peroxidase. The Journal of Comparative Neurology. 1981;**203**:785-798. [PubMed:

reappraisal. In: Rose FC, editor. Physiological Aspects of Clinical Neurology. Oxford: Blackwell Scientific; 1977. pp. 279-293

Psychiatry. 1940;**44**:43-75

Surgery. 1940;**41**:813-856

6173403]

in the cat as determined by the

[35] Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain *Macaca nemestrina*: A c-fos immunocytochemical study. Journal of Anatomy. 1997;**190**:367-375. [PMCID: PMC1467617] [PubMed: 9147223]

Pain. 2003;**106**:81-89

[28] Goadsby PJ, Holland PR, Martinsoliveira M, Hoffmann J, Schankin C, Akerman S.

Reviews. 2017;**97**:553-622

g1416

11198295]

[19] Chalmer MA, Hansen TF, Lebedeva ER, et al. Proposed new diagnostic criteria for chronic migraine. Cephalalgia. 2020;**40**(4):399-406. DOI:

10.1177/0333102419877171

[20] Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010;

[21] Katsarava Z et al. Primary headache disorders in the Republic of Georgia Prevalence and risk factors. Neurology.

[22] Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998;**38**:497-506

[24] Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Current Pain and Headache

[25] Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. Journal of Neurology,

Neurosurgery, and Psychiatry. 2010;**81**:

[26] Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: A systematic review. Headache. 2019;

[27] Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily

[23] Yoon MS et al. Prevalence of primary headaches in Germany: Results of the German Headache Consortium Study. The Journal of Headache and

2004;**44**:684-691

*Chronic Migraine*

**30**(5):599-609

2009;**73**:1796-1803

Pain. 2012;**13**:215-223

Reports. 2012;**16**(1):86-92

428-432

**99**

**59**(3):306-338

[10] Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: Classification and nomenclature. Headache. 2009;**49**:1206-1213

[11] Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: Analysis of factors. Headache. 1982;**22**:66-68

[12] Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache. 1987;**27**:102-106

[13] Silberstein SD, Lipton RB, Solomon SMN. Classification of daily and near daily headaches: Proposed revisions to the IHS criteria. Headache. 1994;**34**:1-7

[14] Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996; **47**:871-875

[15] Manzoni GC, Granella F, Sandrini G, Cavallini A, Zanferrari C, Nappi G. Classification of chronic daily headache by International Headache Society criteria: Limits and new proposals. Cephalalgia. 1995;**15**:37-43

[16] Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. 2004;**24**:1-160

[17] Medrea I, Christie S. Evolution of the concept and clinical implications. Headache. 2018;**58**:1495-1500

[18] Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. Chronic daily headache: Correlation between the 2004 and the 1988 International Headache

#### *Chronic Migraine DOI: http://dx.doi.org/10.5772/intechopen.93314*

Society diagnostic criteria. Headache. 2004;**44**:684-691

**References**

*Migraine*

1-211

1456-1470

301-315

**16**:532

2009;**49**:498-508

[1] Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia. 2018;**38**(1):

headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;**8**:1-96

[10] Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: Classification and nomenclature. Headache. 2009;**49**:1206-1213

[11] Mathew NT, Stubits E, Nigam MP. Transformation of episodic migraine into daily headache: Analysis of factors.

[12] Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine.

Headache. 1982;**22**:66-68

Headache. 1987;**27**:102-106

1994;**34**:1-7

**47**:871-875

[13] Silberstein SD, Lipton RB, Solomon SMN. Classification of daily and near daily headaches: Proposed revisions to the IHS criteria. Headache.

[14] Silberstein SD, Lipton RB,

[15] Manzoni GC, Granella F,

[16] Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders.

Cephalalgia. 2004;**24**:1-160

Headache. 2018;**58**:1495-1500

[17] Medrea I, Christie S. Evolution of the concept and clinical implications.

[18] Bigal ME, Tepper SJ, Sheftell FD, Rapoport AM, Lipton RB. Chronic daily headache: Correlation between the 2004 and the 1988 International Headache

Sliwinski M. Classification of daily and near-daily headaches: Field trial of revised IHS criteria. Neurology. 1996;

Sandrini G, Cavallini A, Zanferrari C, Nappi G. Classification of chronic daily headache by International Headache Society criteria: Limits and new proposals. Cephalalgia. 1995;**15**:37-43

[2] Buse DC et al. Chronic migraine

[3] Blumenfeld AM et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;**31**:

[4] Wiendels NJ et al. Chronic frequent headache in the general population: Comorbidity and quality of life. Cephalalgia. 2006;**26**:1443-1450

[5] Berra E et al. Cost of chronic and episodic migraine. A pilot study from tertiary headache centre northern Italy. The Journal of Headache and Pain. 2015;

[6] Munakata J et al. Economic burden of transformed migraine: results from the American Migraine Prevalence and Prevention (AMPP) Study. Headache.

[7] Magiorkinis E, Diamantis A, Mitsikostas DD, Androutsos G. Headaches in antiquity and during the

early scientific era. Journal of Neurology. 2009;**256**:1215-1220

JAMA. 1962;**179**:717-718

**98**

[8] Ad Hoc Committee on Classification of Headache. Classification of headache.

[9] Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for

sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache. 2012;**52**:

prevalence, disability, and

[19] Chalmer MA, Hansen TF, Lebedeva ER, et al. Proposed new diagnostic criteria for chronic migraine. Cephalalgia. 2020;**40**(4):399-406. DOI: 10.1177/0333102419877171

[20] Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, et al. Global prevalence of chronic migraine: A systematic review. Cephalalgia. 2010; **30**(5):599-609

[21] Katsarava Z et al. Primary headache disorders in the Republic of Georgia Prevalence and risk factors. Neurology. 2009;**73**:1796-1803

[22] Scher AI, Stewart WF, Liberman J, Lipton RB. Prevalence of frequent headache in a population sample. Headache. 1998;**38**:497-506

[23] Yoon MS et al. Prevalence of primary headaches in Germany: Results of the German Headache Consortium Study. The Journal of Headache and Pain. 2012;**13**:215-223

[24] Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. Current Pain and Headache Reports. 2012;**16**(1):86-92

[25] Buse DC, Manack A, Serrano D, Turkel C, Lipton RB. Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. Journal of Neurology, Neurosurgery, and Psychiatry. 2010;**81**: 428-432

[26] Buse DC, Greisman JD, Baigi K, Lipton RB. Migraine progression: A systematic review. Headache. 2019; **59**(3):306-338

[27] Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily

headache in a population-based study. Pain. 2003;**106**:81-89

[28] Goadsby PJ, Holland PR, Martinsoliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: A disorder of sensory processing. Physiological Reviews. 2017;**97**:553-622

[29] Schwedt TJ. Chronic migraine. BMJ. 2014;**348**:g1416. DOI: 10.1136/bmj. g1416

[30] Goadsby PJ. Migraine, aura and cortical spreading depression: Why are we still talking about it? Annals of Neurology. 2001;**49**:4-6. [PubMed: 11198295]

[31] McNaughton FL, Feindel WH. Innervation of intracranial structures: A reappraisal. In: Rose FC, editor. Physiological Aspects of Clinical Neurology. Oxford: Blackwell Scientific; 1977. pp. 279-293

[32] Penfield W, McNaughton FL. Dural headache and the innervation of the dura mater. Archives of Neurology and Psychiatry. 1940;**44**:43-75

[33] Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Archives of Surgery. 1940;**41**:813-856

[34] Marfurt CF. The central projections of trigeminal primary afferent neurons in the cat as determined by the tranganglionic transport of horseradish peroxidase. The Journal of Comparative Neurology. 1981;**203**:785-798. [PubMed: 6173403]

[35] Goadsby PJ, Hoskin KL. The distribution of trigeminovascular afferents in the nonhuman primate brain *Macaca nemestrina*: A c-fos immunocytochemical study. Journal of Anatomy. 1997;**190**:367-375. [PMCID: PMC1467617] [PubMed: 9147223]

[36] Hoskin KL, Zagami A, Goadsby PJ. Stimulation of the middle meningeal artery leads to expression in the trigeminocervical nucleus: A comparative study of monkey and cat. Journal of Anatomy. 1999;**194**:579-588. [PMCID: PMC1467956] [PubMed: 10445825]

[37] SWG D, AKP J, Gyulai F, Clark S, Townsend D, Firestone LL. Pain processing during three levels of noxious stimulation produces differential patterns of central activity. Pain. 1997;**73**:431-445. [PubMed: 9469535]

[38] Burstein R, Jakubowski M. Neural substrate of depression during migraine. Neurological Sciences. 2009;**30**(Suppl 1): S27-S31. [PubMed: 19415422]

[39] Kunkler PE, Kraig RP. Cortical spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. Hippocampus. 2003;**13**: 835-844. [PMCID: PMC2805270] [PubMed: 14620879]

[40] Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One. 2008;**3**: e3799

[41] Schwedt TJ, Larson-Prior L, Coalson RS, Nolan T, Mar S, Ances BM, et al. Allodynia and descending pain modulation in migraine: A resting state functional connectivity analysis. Pain Medicine. 2014;**15**:154-165

[42] Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced byneurophysiological and positron emission tomography studies. Headache. 2007;**47**:996-1003; discussion 1004-7

[43] Lai TH, Chou KH, Fuh JL, et al. Gray matter changes related to

medication overuse in patients with chronic migraine. Cephalalgia. 2016;**36** (14):1324-1333. DOI: 10.1177/<PHONE_NUMBER>630593

acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;**84**(7):

*DOI: http://dx.doi.org/10.5772/intechopen.93314*

Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013; **81**(14):1191-1196. DOI: 10.1212/ WNL.0b013e3182a6cb72

[60] Ramón C, Cernuda-Morollón E, Pascual J. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Current Opinion in Neurology. 2017;**30**(3):

281-286. DOI: 10.1097/ WCO.0000000000000440

[61] Toghae M, Rahimian E,

Abdollahi M, Shoar S, Naderan M. The prevalence of magnetic resonance imaging hyperintensity in migraine patients and its association with migraine headache characteristics and cardiovascular risk factors. Oman Medical Journal. 2015;**30**(3):203-207

[62] Maleki N, Becerra L, Brawn J, Bigal M, Burstein R, Borsook D. Concurrent functional and structural cortical alterations in migraine. Cephalalgia. 2012;**32**(8):607-620

[63] Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M, et al. Cortical abnormalities in episodic migraine: a multi-center 3T MRI study. Cephalalgia. 2019;**39**(5):665-673

[64] Torres-Ferrús M, Ursitti F, Alpuente-Ruiz A, et al. From transformation to chronification of migraine: Pathophysiological and clinical aspects. The Journal of

10.1186/s10194-020-01111-8

2008;**71**(8):559-566

**6**(7):521-532

[65] Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the spopulation: burden, diagnosis, and satisfaction with treatment. Neurology.

Headache and Pain. 2020;**21**(1):42. DOI:

[66] Goldman D, Oroszi G, Ducci F. The genetics of addictions: Uncovering the genes. Nature Reviews. Genetics. 2005;

[52] Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001;**89**(2–3):

[53] Mathew NT, Kurman R, Perez F. Drug induced refractory headache— Clinical features and management. Headache. 1990;**30**(10):634-638. DOI: 10.1111/j.1526-4610.1990.hed3010634.x

[54] Aurora SK, Brin MF. Chronic migraine: An update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache. 2017;**57**(1): 109-125. DOI: 10.1111/head.12999

[55] Su M, Yu S. Chronic migraine: A process of dysmodulation and

sensitization. Molecular Pain. 2018;**14**:<PHONE_NUMBER>767697. DOI: 10.1177/

[56] Ramachandran R. Neurogenic inflammation and its role in migraine. Seminars in Immunopathology. 2018;

[57] Cernuda-Morollón E, Martínez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type a in chronic migraine. Headache. 2014;**54**(6):

[58] Cernuda-Morollon E, Martinez-Camblor P, Alvarez R, Larrosa D, Ramon C, Pascual J. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. 2015;

[59] Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P,

**40**(3):301-314. DOI: 10.1007/

1744806918767697

s00281-018-0676-y

987-995

**35**(4):310-316

**101**

688-695

*Chronic Migraine*

107-110

[44] Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: Specificity, recruitment and plasticity. Brain Research Reviews. 2009;**60**:214-225

[45] May A, Schulte LH. Chronic migraine: Risk factors, mechanisms and treatment. Nature Reviews. Neurology. 2016;**12**(8):455-464. DOI: 10.1038/ nrneurol.2016.93

[46] Stankewitz A, Aderjan D, Eippert F, May A. Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. The Journal of Neuroscience. 2011;**31**(6):1937-1943. DOI: 10.1523/4496-10.2011

[47] Schulte LH, Jürgens TP, May A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: Mistaking symptoms for triggers? The Journal of Headache and Pain. 2015;**16**: 14. DOI: 10.1186/s10194-015-0495-7

[48] Dahlem MA, Kurths J, Ferrari MD, Aihara K, Scheffer M, May A. Understanding migraine using dynamic network biomarkers. Cephalalgia. 2015; **35**(7):627-630. DOI: 10.1177/<PHONE_NUMBER>550108

[49] Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;**62**(5):788-790. DOI: 10.1212/01. wnl.0000113747.18760.d2

[50] Louter MA, Bosker JE, Van Oosterhout WPJ, Van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013; **136**(11):3489-3496

[51] Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective

#### *Chronic Migraine DOI: http://dx.doi.org/10.5772/intechopen.93314*

acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;**84**(7): 688-695

[36] Hoskin KL, Zagami A, Goadsby PJ. Stimulation of the middle meningeal artery leads to expression in the trigeminocervical nucleus: A

medication overuse in patients with chronic migraine. Cephalalgia. 2016;**36**

[44] Heinricher MM, Tavares I, Leith JL, Lumb BM. Descending control of nociception: Specificity, recruitment and plasticity. Brain Research Reviews.

[46] Stankewitz A, Aderjan D, Eippert F,

(14):1324-1333. DOI: 10.1177/

[45] May A, Schulte LH. Chronic migraine: Risk factors, mechanisms and treatment. Nature Reviews. Neurology. 2016;**12**(8):455-464. DOI: 10.1038/

May A. Trigeminal nociceptive transmission in migraineurs predicts migraine attacks. The Journal of Neuroscience. 2011;**31**(6):1937-1943.

DOI: 10.1523/4496-10.2011

[47] Schulte LH, Jürgens TP, May A. Photo-, osmo- and phonophobia in the premonitory phase of migraine: Mistaking symptoms for triggers? The Journal of Headache and Pain. 2015;**16**: 14. DOI: 10.1186/s10194-015-0495-7

[48] Dahlem MA, Kurths J, Ferrari MD,

Understanding migraine using dynamic network biomarkers. Cephalalgia. 2015;

Aihara K, Scheffer M, May A.

**35**(7):627-630. DOI: 10.1177/

wnl.0000113747.18760.d2

**136**(11):3489-3496

[50] Louter MA, Bosker JE, Van Oosterhout WPJ, Van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;

[51] Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective

[49] Katsarava Z, Schneeweiss S, Kurth T, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;**62**(5):788-790. DOI: 10.1212/01.

0333102414550108

0333102416630593

2009;**60**:214-225

nrneurol.2016.93

comparative study of monkey and cat. Journal of Anatomy. 1999;**194**:579-588. [PMCID: PMC1467956] [PubMed:

[37] SWG D, AKP J, Gyulai F, Clark S, Townsend D, Firestone LL. Pain processing during three levels of noxious stimulation produces

differential patterns of central activity. Pain. 1997;**73**:431-445. [PubMed:

[38] Burstein R, Jakubowski M. Neural substrate of depression during migraine. Neurological Sciences. 2009;**30**(Suppl 1):

S27-S31. [PubMed: 19415422]

[PubMed: 14620879]

e3799

[39] Kunkler PE, Kraig RP. Cortical spreading depression bilaterally activates the caudal trigeminal nucleus in rodents. Hippocampus. 2003;**13**: 835-844. [PMCID: PMC2805270]

[40] Moulton EA, Burstein R, Tully S, Hargreaves R, Becerra L, Borsook D. Interictal dysfunction of a brainstem descending modulatory center in migraine patients. PLoS One. 2008;**3**:

[41] Schwedt TJ, Larson-Prior L,

Medicine. 2014;**15**:154-165

[42] Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced byneurophysiological and positron emission tomography studies.

Headache. 2007;**47**:996-1003;

[43] Lai TH, Chou KH, Fuh JL, et al. Gray matter changes related to

discussion 1004-7

**100**

Coalson RS, Nolan T, Mar S, Ances BM, et al. Allodynia and descending pain modulation in migraine: A resting state functional connectivity analysis. Pain

10445825]

*Migraine*

9469535]

[52] Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2001;**89**(2–3): 107-110

[53] Mathew NT, Kurman R, Perez F. Drug induced refractory headache— Clinical features and management. Headache. 1990;**30**(10):634-638. DOI: 10.1111/j.1526-4610.1990.hed3010634.x

[54] Aurora SK, Brin MF. Chronic migraine: An update on physiology, imaging, and the mechanism of action of two available pharmacologic therapies. Headache. 2017;**57**(1): 109-125. DOI: 10.1111/head.12999

[55] Su M, Yu S. Chronic migraine: A process of dysmodulation and sensitization. Molecular Pain. 2018;**14**:<PHONE_NUMBER>767697. DOI: 10.1177/<PHONE_NUMBER>767697

[56] Ramachandran R. Neurogenic inflammation and its role in migraine. Seminars in Immunopathology. 2018; **40**(3):301-314. DOI: 10.1007/ s00281-018-0676-y

[57] Cernuda-Morollón E, Martínez-Camblor P, Ramón C, Larrosa D, Serrano-Pertierra E, Pascual J. CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type a in chronic migraine. Headache. 2014;**54**(6): 987-995

[58] Cernuda-Morollon E, Martinez-Camblor P, Alvarez R, Larrosa D, Ramon C, Pascual J. Increased VIP levels in peripheral blood outside migraine attacks as a potential biomarker of cranial parasympathetic activation in chronic migraine. Cephalalgia. 2015; **35**(4):310-316

[59] Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013; **81**(14):1191-1196. DOI: 10.1212/ WNL.0b013e3182a6cb72

[60] Ramón C, Cernuda-Morollón E, Pascual J. Calcitonin gene-related peptide in peripheral blood as a biomarker for migraine. Current Opinion in Neurology. 2017;**30**(3): 281-286. DOI: 10.1097/ WCO.0000000000000440

[61] Toghae M, Rahimian E, Abdollahi M, Shoar S, Naderan M. The prevalence of magnetic resonance imaging hyperintensity in migraine patients and its association with migraine headache characteristics and cardiovascular risk factors. Oman Medical Journal. 2015;**30**(3):203-207

[62] Maleki N, Becerra L, Brawn J, Bigal M, Burstein R, Borsook D. Concurrent functional and structural cortical alterations in migraine. Cephalalgia. 2012;**32**(8):607-620

[63] Magon S, May A, Stankewitz A, Goadsby PJ, Schankin C, Ashina M, et al. Cortical abnormalities in episodic migraine: a multi-center 3T MRI study. Cephalalgia. 2019;**39**(5):665-673

[64] Torres-Ferrús M, Ursitti F, Alpuente-Ruiz A, et al. From transformation to chronification of migraine: Pathophysiological and clinical aspects. The Journal of Headache and Pain. 2020;**21**(1):42. DOI: 10.1186/s10194-020-01111-8

[65] Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the spopulation: burden, diagnosis, and satisfaction with treatment. Neurology. 2008;**71**(8):559-566

[66] Goldman D, Oroszi G, Ducci F. The genetics of addictions: Uncovering the genes. Nature Reviews. Genetics. 2005; **6**(7):521-532

[67] Vila-Pueyo M, Fernandez-Castillo N, Cormand B, Pozo-Rosich P, Macaya A. Epigenetic changes in a rat model of migraine with aura. The Journal of Headache and Pain. 2014;**15** (Suppl 1):A6. DOI: 10.1186/1129-2377- 15-S1-A6

[68] Nelson ED, Monteggia LM. Epigenetics in the mature mammalian brain: Effects on behavior and synaptic transmission. Neurobiology of Learning and Memory. 2011;**96**(1):53-60

[69] Bigal ME, Lipton RB. Migraine chronification. Current Neurology and Neuroscience Reports. 2011;**11**(2): 139-148

[70] Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;**56**(suppl 1):S20 LP-S20S28

[71] Bigal ME, Lipton RB. Obesity and chronic daily headache. Current Pain and Headache Reports. 2008;**12**(1): 56-61

[72] Ashina S, Serrano D, Lipton RB, et al. Depression and risk of transformation of episodic to chronic migraine. The Journal of Headache and Pain. 2012;**13**(8):615-624. DOI: 10.1007/ s10194-012-0479-9

[73] Finocchi C, Strada L. Sex-related differences in migraine. Neurological Sciences. 2014;**35**(Suppl 1):207-213

[74] Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American migraine study II. Headache. 2001;**41**(7):646-657

[75] Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;**35**(7): 563-578. DOI: 10.1177/<PHONE_NUMBER>552532

[76] Lu S-R, Fuh J-L, Wang S-J, Juang K-D, Chen S-P, Liao Y-C, et al. Incidence and risk factors of chronic daily headache in young adolescents: A school cohort study. Pediatrics. 2013;**132**(1):e9 e16

Adams A, et al. Sleep disorders among people with migraine: Results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache.

*DOI: http://dx.doi.org/10.5772/intechopen.93314*

[92] Ferrari A, Baraldi C, Sternieri E. Medication overuse and chronic

2015;**11**(7):1127-1144

migraine: A critical review according to clinical pharmacology. Expert Opinion on Drug Metabolism & Toxicology.

[93] Buse DC, Loder EW, Gorman JA, et al.

[94] Russell MB, Ducros A. Sporadic and

Pathophysiological mechanisms, clinical

management. Lancet Neurology. 2011; **10**(5):457-470. DOI: 10.1016/S1474

[95] Diener HC, Solbach K, Holle D, Gaul C. Integrated care for chronic migraine patients: Epidemiology, burden, diagnosis and treatment options. Clinical Medicine (London, England). 2015;**15**(4):344-350. DOI: 10.7861/clinmedicine.15-4-344

[96] Dodick DW, Silberstein SD. Migraine prevention. Practical Neurology. 2007;**7**:383-393

treatment of chronic migraine. Therapeutic Advances in Chronic Diseases. 2015;**6**(3):115-123. DOI: 10.1177/2040622315579627

[97] Weatherall MW. The diagnosis and

[98] Yancey JR, Sheridan R, Koren KG. Chronic daily headache: Diagnosis and management. American Family Physician. 2014;**89**(8):642-648

[99] British Association for the Study of Headache (BASH). National Headache Management System for Adults

Guidelines. 2019. Available from: www.

bash.org.uk

familial hemiplegic migraine:

characteristics, diagnosis, and

4422(11)70048-5

Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;**53**(8): 1278-1299. DOI: 10.1111/head.12150

[84] Bigal ME, Lipton RB. What predicts the change from episodic tochronic migraine? Current Opinion in Neurology. 2009;**22**(3):269-276

[85] Lipton RB, Fanning KM, Buse DC, Martin VT, Hohaia LB, Adams AM, et al. Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO study. Neurology.

[86] Buse D, Silberstein S, Manack A,

Psychiatric comorbidities of episodic and chronic migraine. Journal of Neurology. 2013;**260**(8):1960-1969

[87] Kayhan F, Ilik F. Prevalence of personality disorders in patients with chronic migraine. Comprehensive

[88] Plesh O, Adams SH, Gansky SA. Self-reported comorbid pains in severe headaches or migraines in a US national sample. Headache. 2012;**52**(6):946-956

[89] Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Annals of Neurology. 2008;

[90] Lampl C, Huber G, Haas S, Rittberger E, Diener HC. Difference in triptan effect in patients with migraine and early allodynia. Cephalalgia. 2008;

[91] Kristoffersen ES, Grande RB, Aaseth K, Russell MB, Lundqvist C. Medication-overuse headache detoxification reduces headache disability—The Akershus study of chronic headache. European Journal of Neurology. 2018;**25**(9):1140-1147

2019;**93**(24):e2224-e2236

Papapetropoulos S, Lipton R.

Psychiatry. 2016;**68**:60-64

**63**(2):148-158

**28**(10):1031-1038

**103**

2019;**59**(1):32-45

*Chronic Migraine*

[77] Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: A population-based study. Neurology. 2004;**63**(11):2022-2027

[78] Santos IS, Goulart AC, Passos VM, del Carmen MM, Lotufo PA, Bensenor IM. Obesity, abdominal obesity and migraine: A crosssectional analysis of ELSA-Brasil baseline data. Cephalalgia. 2015;**35**(5):426-436

[79] Ornello R, Ripa P, Pistoia F, Degan D, Tiseo C, Carolei A, et al. Migraine and body mass index categories: A systematic review and meta-analysis of observational studies. The Journal of Headache and Pain. 2015;**16**:27

[80] Fava A, Pirritano D, Consoli D, et al. Chronic migraine in women is associated with insulin resistance: A cross-sectional study. European Journal of Neurology. 2014;**21**(2):267-272. DOI: 10.1111/ene.12289

[81] Peterlin BL, Rosso AL, Rapoport AM, Scher AI. Obesity and migraine: The effect of age, gender and adipose tissue distribution. Headache. 2010;**50**(1):52-62. DOI: 10.1111/ j.1526-4610.2009.01459.x

[82] He Z, Dong L, Zhang Y, Kong Q, Tan G, Zhou J. Metabolic syndrome in female migraine patients is associated with medication overuse headache: A clinic-based study in China. European Journal of Neurology. 2015;**22**(8): 1228-1234. DOI: 10.1111/ene.12732

[83] Buse DC, Rains JC, Pavlovic JM, Fanning KM, Reed ML, Manack

#### *Chronic Migraine DOI: http://dx.doi.org/10.5772/intechopen.93314*

Adams A, et al. Sleep disorders among people with migraine: Results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache. 2019;**59**(1):32-45

[67] Vila-Pueyo M, Fernandez-Castillo N, Cormand B, Pozo-Rosich P, Macaya A. Epigenetic changes in a rat model of migraine with aura. The Journal of Headache and Pain. 2014;**15** (Suppl 1):A6. DOI: 10.1186/1129-2377563-578. DOI: 10.1177/<PHONE_NUMBER>552532

e16

2015;**16**:27

10.1111/ene.12289

[76] Lu S-R, Fuh J-L, Wang S-J, Juang K-D, Chen S-P, Liao Y-C, et al. Incidence and risk factors of chronic daily

headache in young adolescents: A school cohort study. Pediatrics. 2013;**132**(1):e9-

[77] Scher AI, Stewart WF, Lipton RB. Caffeine as a risk factor for chronic daily headache: A population-based study. Neurology. 2004;**63**(11):2022-2027

[78] Santos IS, Goulart AC, Passos VM,

[79] Ornello R, Ripa P, Pistoia F, Degan D, Tiseo C, Carolei A, et al. Migraine and body mass index categories: A systematic review and meta-analysis of observational studies. The Journal of Headache and Pain.

[80] Fava A, Pirritano D, Consoli D, et al.

Chronic migraine in women is associated with insulin resistance: A cross-sectional study. European Journal of Neurology. 2014;**21**(2):267-272. DOI:

[81] Peterlin BL, Rosso AL,

Rapoport AM, Scher AI. Obesity and migraine: The effect of age, gender and adipose tissue distribution. Headache. 2010;**50**(1):52-62. DOI: 10.1111/ j.1526-4610.2009.01459.x

[82] He Z, Dong L, Zhang Y, Kong Q, Tan G, Zhou J. Metabolic syndrome in female migraine patients is associated with medication overuse headache: A clinic-based study in China. European Journal of Neurology. 2015;**22**(8): 1228-1234. DOI: 10.1111/ene.12732

[83] Buse DC, Rains JC, Pavlovic JM, Fanning KM, Reed ML, Manack

del Carmen MM, Lotufo PA, Bensenor IM. Obesity, abdominal obesity and migraine: A crosssectional analysis of ELSA-Brasil baseline data. Cephalalgia. 2015;**35**(5):426-436

[68] Nelson ED, Monteggia LM. Epigenetics in the mature mammalian brain: Effects on behavior and synaptic transmission. Neurobiology of Learning

and Memory. 2011;**96**(1):53-60

[69] Bigal ME, Lipton RB. Migraine chronification. Current Neurology and Neuroscience Reports. 2011;**11**(2):

[70] Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology. 2001;**56**(suppl 1):S20 LP-S20S28

[71] Bigal ME, Lipton RB. Obesity and chronic daily headache. Current Pain and Headache Reports. 2008;**12**(1):

[72] Ashina S, Serrano D, Lipton RB,

transformation of episodic to chronic migraine. The Journal of Headache and Pain. 2012;**13**(8):615-624. DOI: 10.1007/

[73] Finocchi C, Strada L. Sex-related differences in migraine. Neurological Sciences. 2014;**35**(Suppl 1):207-213

[74] Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American migraine study II. Headache. 2001;**41**(7):646-657

[75] Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;**35**(7):

et al. Depression and risk of

s10194-012-0479-9

15-S1-A6

*Migraine*

139-148

56-61

**102**

[84] Bigal ME, Lipton RB. What predicts the change from episodic tochronic migraine? Current Opinion in Neurology. 2009;**22**(3):269-276

[85] Lipton RB, Fanning KM, Buse DC, Martin VT, Hohaia LB, Adams AM, et al. Migraine progression in subgroups of migraine based on comorbidities: Results of the CaMEO study. Neurology. 2019;**93**(24):e2224-e2236

[86] Buse D, Silberstein S, Manack A, Papapetropoulos S, Lipton R. Psychiatric comorbidities of episodic and chronic migraine. Journal of Neurology. 2013;**260**(8):1960-1969

[87] Kayhan F, Ilik F. Prevalence of personality disorders in patients with chronic migraine. Comprehensive Psychiatry. 2016;**68**:60-64

[88] Plesh O, Adams SH, Gansky SA. Self-reported comorbid pains in severe headaches or migraines in a US national sample. Headache. 2012;**52**(6):946-956

[89] Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, et al. Cutaneous allodynia in the migraine population. Annals of Neurology. 2008; **63**(2):148-158

[90] Lampl C, Huber G, Haas S, Rittberger E, Diener HC. Difference in triptan effect in patients with migraine and early allodynia. Cephalalgia. 2008; **28**(10):1031-1038

[91] Kristoffersen ES, Grande RB, Aaseth K, Russell MB, Lundqvist C. Medication-overuse headache detoxification reduces headache disability—The Akershus study of chronic headache. European Journal of Neurology. 2018;**25**(9):1140-1147

[92] Ferrari A, Baraldi C, Sternieri E. Medication overuse and chronic migraine: A critical review according to clinical pharmacology. Expert Opinion on Drug Metabolism & Toxicology. 2015;**11**(7):1127-1144

[93] Buse DC, Loder EW, Gorman JA, et al. Sex differences in the prevalence, symptoms, and associated features of migraine, probable migraine and other severe headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache. 2013;**53**(8): 1278-1299. DOI: 10.1111/head.12150

[94] Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: Pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurology. 2011; **10**(5):457-470. DOI: 10.1016/S1474 4422(11)70048-5

[95] Diener HC, Solbach K, Holle D, Gaul C. Integrated care for chronic migraine patients: Epidemiology, burden, diagnosis and treatment options. Clinical Medicine (London, England). 2015;**15**(4):344-350. DOI: 10.7861/clinmedicine.15-4-344

[96] Dodick DW, Silberstein SD. Migraine prevention. Practical Neurology. 2007;**7**:383-393

[97] Weatherall MW. The diagnosis and treatment of chronic migraine. Therapeutic Advances in Chronic Diseases. 2015;**6**(3):115-123. DOI: 10.1177/2040622315579627

[98] Yancey JR, Sheridan R, Koren KG. Chronic daily headache: Diagnosis and management. American Family Physician. 2014;**89**(8):642-648

[99] British Association for the Study of Headache (BASH). National Headache Management System for Adults Guidelines. 2019. Available from: www. bash.org.uk

[100] Welch KM, Goadsby PJ. Chronic daily headache: Nosology and pathophysiology. Current Opinion in Neurology. 2002;**15**(3):287-295. DOI: 10.1097/00019052-200206000-00011

[101] Viana M, Bottiroli S, Sances G, et al. Factors associated to chronic migraine with medication overuse: A cross-sectional study. Cephalalgia. 2018; **38**(14):2045-2057. DOI: 10.1177/<PHONE_NUMBER>761047

[102] Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: Implications for diagnosis, treatment and clinical trial design. The Journal of Headache and Pain. 2017; **18**(1):101

[103] Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;**46**(9):1334-1343

[104] Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002; **59**(7):1011-1014

[105] Diener HC, Holle-Lee D, Nägel S, Gaul C. Differenzialtherapie von Kopfschmerzen [Headache Treatment]. Dtsch Med Wochenschr. 2017;**142**(6): 418-426. DOI: 10.1055/s-0042-121336

[106] Totzeck A, Gaul C. The role of opioids in the treatment of primary headache disorders. Schmerz. 2014; **28**(2):135-140

[107] Dussor G, Yan J, Xie JY, Ossipov MH, Dodick DW, Porreca F. Targeting TRP channels for novel migraine therapeutics. ACS Chemical Neuroscience. 2014;**5**(11):1085-1096

[108] Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology. Nature Reviews. Neurology. 2010; **6**(10):573-582

[117] Aurora SK, Dodick DW,

[118] Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind,

[119] Dodick DW, Turkel CC,

[120] Blumenfeld AM, Schim JD,

treatment of episodic or chronic migraine. Headache. 2008;**48**(2):

[121] Mathew NT, Jaffri SF. A double-blind comparison of

[122] Magalhaes E, Menezes C, Cardeal M, Melo A. Botulinum toxin type a versus amitriptyline for the treatment of chronic daily migraine. Clinical Neurology and Neurosurgery.

[123] Tassorelli C, Aguggia M, De Tommaso M, Geppetti P, Grazzi L, Pini LA, et al. Onabotulinumtoxin a for the management of chronic migraine in

**49**(10):1466-1478

2010;**112**(6):463-466

**105**

onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009;

210-220

Chippendale TJ. Botulinum toxin type a and divalproex sodium for prophylactic

2010;**30**(7):793-803

*Chronic Migraine*

2010;**30**(7):804-814

Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind,

*DOI: http://dx.doi.org/10.5772/intechopen.93314*

current clinical practice: Results of a survey of sixty-three Italian headache centers. The Journal of Headache and

Geppetti P, et al. Optimizing the longterm management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics.

[125] Winner PK, Blumenfield AM, Eross EJ, et al. Long-term safety and tolerability of onabotulinumtoxinA treatment in patients with chronic migraine: Results of the COMPEL study. Drug Safety. 2019;**42**(8):1013-1024

[126] Simpson LL. The origin, structure,

[127] Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25.

[128] Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum

neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia. 2014;**34**:853-869

[129] Whitcup SM, Turkel CC,

[130] Frampton JE, Silberstein S. OnabotulinumtoxinA: A review in the prevention of chronic migraine. Drugs.

[131] Agostoni EC, Barbanti P,

Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: A narrative review. The Journal of Headache and Pain. 2019;**20**:92

2018;**78**(5):589-600

DeGryse RE, Brin MF. Development of onabotulinumtoxinA for chronic migraine. Annals of the New York Academy of Sciences. 2014;**1329**:67-80

and pharmacological activity of botulinum toxin. Pharmacological

Reviews. 1981;**33**:155-188

Nature. 1993;**365**:160-163

[124] Tassorelli C, Tedeschi G, Sarchielli P, Pini LA, Grazzi L,

Pain. 2017;**18**(1):66

2018;**18**(2):167-176

randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia.

randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia.

DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;**50**(6):921-936

[109] Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology. 2013;**80**(8):697-704

[110] Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallelgroup, shamcontrolled trial. Lancet Neurology. 2010;**9**(4):373-380

[111] Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016;**87**(5):529-538

[112] Sarchielli P, Granella F, Prudenzano MP, Pini LA, Guidetti V, Bono G, et al. Italian guidelines for primary headaches: 2012 revised version. The Journal of Headache and Pain. 2012;**13**(Suppl 2):S31-S70

[113] Cho SJ, Song TJ, Chu MK. Treatment update of chronic migraine. Current Pain and Headache Reports. 2017;**21**(6):26

[114] Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine prophylaxis adherence and persistence. Journal of Managed Care Pharmacy. 2014;**20**(1):22-33

[115] Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015; **35**(6):478-488

[116] BOTOX (OnabotulinumtoxinA for Injection, for Intramuscular, Intradetrusor, or Intradermal Use). Irvine, CA: Full Prescribing Information, Allergan, Inc; 2013

#### *Chronic Migraine DOI: http://dx.doi.org/10.5772/intechopen.93314*

[100] Welch KM, Goadsby PJ. Chronic

Nature Reviews. Neurology. 2010;

[109] Schoenen J, Vandersmissen B, Jeangette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: A randomized controlled trial. Neurology. 2013;**80**(8):697-704

[110] Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: A randomised, double-blind, parallelgroup, shamcontrolled trial. Lancet Neurology. 2010;**9**(4):373-380

[111] Silberstein SD, Calhoun AH, Lipton RB, et al. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016;**87**(5):529-538

[112] Sarchielli P, Granella F,

[113] Cho SJ, Song TJ, Chu MK.

2017;**21**(6):26

2014;**20**(1):22-33

**35**(6):478-488

Treatment update of chronic migraine. Current Pain and Headache Reports.

[114] Hepp Z, Bloudek LM, Varon SF. Systematic review of migraine

prophylaxis adherence and persistence. Journal of Managed Care Pharmacy.

[115] Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;

[116] BOTOX (OnabotulinumtoxinA for

Injection, for Intramuscular, Intradetrusor, or Intradermal Use).

Irvine, CA: Full Prescribing Information, Allergan, Inc; 2013

Prudenzano MP, Pini LA, Guidetti V, Bono G, et al. Italian guidelines for primary headaches: 2012 revised version. The Journal of Headache and Pain. 2012;**13**(Suppl 2):S31-S70

**6**(10):573-582

pathophysiology. Current Opinion in Neurology. 2002;**15**(3):287-295. DOI: 10.1097/00019052-200206000-00011

[101] Viana M, Bottiroli S, Sances G, et al. Factors associated to chronic migraine with medication overuse: A cross-sectional study. Cephalalgia. 2018;

**38**(14):2045-2057. DOI: 10.1177/

[102] Serrano D, Lipton RB, Scher AI, Reed ML, Stewart WBF, Adams AM, et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: Implications for diagnosis, treatment and clinical trial design. The Journal of Headache and Pain. 2017;

[103] Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache. 2006;**46**(9):1334-1343

headache following overuse of different acute headache drugs. Neurology. 2002;

[105] Diener HC, Holle-Lee D, Nägel S, Gaul C. Differenzialtherapie von Kopfschmerzen [Headache Treatment]. Dtsch Med Wochenschr. 2017;**142**(6): 418-426. DOI: 10.1055/s-0042-121336

[106] Totzeck A, Gaul C. The role of opioids in the treatment of primary headache disorders. Schmerz. 2014;

Ossipov MH, Dodick DW, Porreca F. Targeting TRP channels for novel migraine therapeutics. ACS Chemical Neuroscience. 2014;**5**(11):1085-1096

[108] Ho TW, Edvinsson L, Goadsby PJ. CGRP and its receptors provide new insights into migraine pathophysiology.

[107] Dussor G, Yan J, Xie JY,

[104] Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse

0333102418761047

**18**(1):101

**59**(7):1011-1014

**28**(2):135-140

**104**

daily headache: Nosology and

*Migraine*

[117] Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. Onabotulinumtoxin A for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;**30**(7):793-803

[118] Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;**30**(7):804-814

[119] Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;**50**(6):921-936

[120] Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type a and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache. 2008;**48**(2): 210-220

[121] Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache. 2009; **49**(10):1466-1478

[122] Magalhaes E, Menezes C, Cardeal M, Melo A. Botulinum toxin type a versus amitriptyline for the treatment of chronic daily migraine. Clinical Neurology and Neurosurgery. 2010;**112**(6):463-466

[123] Tassorelli C, Aguggia M, De Tommaso M, Geppetti P, Grazzi L, Pini LA, et al. Onabotulinumtoxin a for the management of chronic migraine in current clinical practice: Results of a survey of sixty-three Italian headache centers. The Journal of Headache and Pain. 2017;**18**(1):66

[124] Tassorelli C, Tedeschi G, Sarchielli P, Pini LA, Grazzi L, Geppetti P, et al. Optimizing the longterm management of chronic migraine with onabotulinumtoxinA in real life. Expert Review of Neurotherapeutics. 2018;**18**(2):167-176

[125] Winner PK, Blumenfield AM, Eross EJ, et al. Long-term safety and tolerability of onabotulinumtoxinA treatment in patients with chronic migraine: Results of the COMPEL study. Drug Safety. 2019;**42**(8):1013-1024

[126] Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacological Reviews. 1981;**33**:155-188

[127] Blasi J, Chapman ER, Link E, et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993;**365**:160-163

[128] Burstein R, Zhang X, Levy D, Aoki KR, Brin MF. Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains. Cephalalgia. 2014;**34**:853-869

[129] Whitcup SM, Turkel CC, DeGryse RE, Brin MF. Development of onabotulinumtoxinA for chronic migraine. Annals of the New York Academy of Sciences. 2014;**1329**:67-80

[130] Frampton JE, Silberstein S. OnabotulinumtoxinA: A review in the prevention of chronic migraine. Drugs. 2018;**78**(5):589-600

[131] Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: A narrative review. The Journal of Headache and Pain. 2019;**20**:92 [132] Cernuda-Morollon E, Ramon C, Martinez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J. OnabotulinumtoxinA decreases interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;**156**: 820-824

[133] Guerzoni S, Pellesi L, Baraldi C, Pini LA. Increased efficacy of regularly repeated cycles with onabotulinumtoxinA in MOH patients beyond the first year of treatment. The Journal of Headache and Pain. 2015;**17**:48

[134] Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. Journal of Neurology, Neurosurgery, and Psychiatry. 2015; **86**(9):996-1001

[135] Sarchielli P, Romoli M, Corbelli I, Bernetti L, Verzina A, Brahimi E, et al. Stopping onabotulinum treatment after the first two cycles might not be justified: Results of a real-life monocentric prospective study in chronic migraine. Frontiers in Neurology. 2017;**8**:655

[136] Barbanti P, Ferroni P. Onabotulinum toxin A in the treatment of chronic migraine: Patient selection and special considerations. Journal of Pain Research. 2017;**10**:2319-2329

[137] Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack AA. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The Journal of Headache and Pain. 2018;**19**(1):13

[138] Matharu M, Pascual J, Nilsson Remahl I, Straube A, Lum A, Davar G, et al. Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an

observational study in Europe. Cephalalgia. 2017;**37**(14):1384-1397

[139] Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P, et al. Guideline on the use of onabotulinumtoxinA in chronic migraine: A consensus statement from the European Headache Federation. The Journal of Headache and Pain. 2018;**19**(1):91

[147] Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache. Headache.

*DOI: http://dx.doi.org/10.5772/intechopen.93314*

Available from: https://www.lundbeck. com/upload/us/files/pdf/Products/ Vyepti\_PI\_US\_EN.pdf [Accessed: 05

[155] Dhillon S. Eptinezumab: First approval. Drugs. 2020;**80**:733-739

[156] Goldberg SW, Silberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs. 2015;**29**(6):

[157] Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, et al. Blocking CGRP in migraine patients a review of pros and cons. The Journal of Headache and Pain. 2017;**18**(1):96

[158] Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. British Journal of Clinical Pharmacology. 2015;**80**(2):193-199

[159] Israel H, Neeb L, Reuter U. CGRP

monoclonal antibodies for the preventative treatment of migraine. Current Pain and Headache Reports.

[160] Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. The New England Journal of

Medicine. 2017;**377**:2113-2122

[162] Dodic DW, Lipton RB,

Silberstein S, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;**39**(9):1075-1085

[163] Sacco S, Bendtsen L, Ashina M, et al. European headache federation

[161] Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebocontrolled REGAIN study. Neurology.

2018;**22**(5):38

2018;**91**:e1-e11

March 2020]

443-452

[148] Novartis Europharm Limited. Aimovig (erenumab) for Injection: Summary of Product Characteristics. 2018. Available from: https://www.ema. europa.eu/documents/product-informa tion/aimovig-epar-product-informa tion\_en.pdf [Accessed: 11 July 2019]

[149] Amgen Inc. Aimovig™ (Erenumab-aooe) Injection, for Subcutaneous Use: US Prescribing

[150] Teva GmbH. Ajovy (Fremanezumab) for Injection: Summary of Product Characteristics. 2018. Available from: https://www.ema. europa.eu/documents/product-informa tion/ajovy-epar-product-information\_ en.pdf [Accessed: 11 July 2019]

[151] Teva Pharmaceutical Industries Ltd. Ajovy™ (Fremanezumab-vfrm) Injection, for Subcutaneous Use. 2018. Available from: https://www.accessdata. fda.gov/drugsatfda\_docs/label/2018/ 761089s000lbl.pdf [Accessed: 11 July

[152] Eli Lilly and Company. Emgality (Galcanezumab-glnm) Injection, for Subcutaneous Use: US Prescribing Information. 2018. Available from: https://www.accessdata.fda.gov/drugsa tfda\_docs/label/2018/761063s000lbl.

[153] Eli Lilly Nederland BV. Emgality (Galcanezumab) for Injection: Summary

Available from: https://www.ema.europa. eu/en/documents/product-information/ emgality-epar-product-information\_en.

[154] Lundbeck. Vyepti (Eptinezumabjjmr): US Prescribing Information. 2020.

of Product Characteristics. 2018.

pdf [Accessed: 11 July 2019]

pdf [Accessed: 11 July 2019]

2007;**47**:13-21

*Chronic Migraine*

Information

2019]

**107**

[140] Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multicenter double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;**51**:21-32

[141] Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebocontrolled study. Cephalalgia. 2007; **27**(7):814-823

[142] Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache. 2007;**47**(2):170-180

[143] Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;**10**(7):e0130733

[144] Lainez MJ, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. European Journal of Neurology. 2007;**14**(8):900-906

[145] Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia. 2002;**22**:491-512

[146] Ruiz L, Ferrandi D. Topiramate in migraine progression. The Journal of Headache and Pain. 2009;**10**:419-422

#### *Chronic Migraine DOI: http://dx.doi.org/10.5772/intechopen.93314*

[147] Limmroth V, Biondi D, Pfeil J, Schwalen S. Topiramate in patients with episodic migraine: Reducing the risk for chronic forms of headache. Headache. 2007;**47**:13-21

[132] Cernuda-Morollon E, Ramon C, Martinez-Camblor P, Serrano-Pertierra observational study in Europe. Cephalalgia. 2017;**37**(14):1384-1397

et al. Guideline on the use of

[139] Bendtsen L, Sacco S, Ashina M, Mitsikostas D, Ahmed F, Pozo-Rosich P,

onabotulinumtoxinA in chronic migraine: A consensus statement from the European Headache Federation. The Journal of Headache and Pain. 2018;**19**(1):91

[140] Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multicenter double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache. 2011;**51**:21-32

[141] Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebocontrolled study. Cephalalgia. 2007;

[142] Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled trial. Headache.

[143] Jackson JL, Cogbill E, Santana-Davila R, et al. A comparative

effectiveness meta-analysis of drugs for the prophylaxis of migraine headache. PLoS One. 2015;**10**(7):e0130733

[144] Lainez MJ, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. European Journal of

[146] Ruiz L, Ferrandi D. Topiramate in migraine progression. The Journal of Headache and Pain. 2009;**10**:419-422

Neurology. 2007;**14**(8):900-906

[145] Silberstein SD, Goadsby PJ. Migraine: Preventive treatment. Cephalalgia. 2002;**22**:491-512

**27**(7):814-823

2007;**47**(2):170-180

interictal CGRP plasma levels in patients with chronic migraine. Pain. 2015;**156**:

[133] Guerzoni S, Pellesi L, Baraldi C, Pini LA. Increased efficacy of regularly repeated cycles with onabotulinumtoxinA in MOH patients beyond the first year of treatment. The Journal of Headache and

[134] Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, et al. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. Journal of Neurology, Neurosurgery, and Psychiatry. 2015;

[135] Sarchielli P, Romoli M, Corbelli I, Bernetti L, Verzina A, Brahimi E, et al. Stopping onabotulinum treatment after the first two cycles might not be justified: Results of a real-life monocentric prospective study in chronic migraine. Frontiers in

Onabotulinum toxin A in the treatment of chronic migraine: Patient selection and special considerations. Journal of Pain Research. 2017;**10**:2319-2329

Freeman MC, Orejudos A, Manack AA. Long-term study of the efficacy and safety of onabotulinumtoxinA for the prevention of chronic migraine: COMPEL study. The Journal of Headache and Pain. 2018;**19**(1):13

OnabotulinumtoxinA decreases

E, Larrosa D, Pascual J.

820-824

*Migraine*

Pain. 2015;**17**:48

**86**(9):996-1001

Neurology. 2017;**8**:655

[136] Barbanti P, Ferroni P.

[137] Blumenfeld AM, Stark RJ,

[138] Matharu M, Pascual J, Nilsson Remahl I, Straube A, Lum A, Davar G,

onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an

et al. Utilization and safety of

**106**

[148] Novartis Europharm Limited. Aimovig (erenumab) for Injection: Summary of Product Characteristics. 2018. Available from: https://www.ema. europa.eu/documents/product-informa tion/aimovig-epar-product-informa tion\_en.pdf [Accessed: 11 July 2019]

[149] Amgen Inc. Aimovig™ (Erenumab-aooe) Injection, for Subcutaneous Use: US Prescribing Information

[150] Teva GmbH. Ajovy (Fremanezumab) for Injection: Summary of Product Characteristics. 2018. Available from: https://www.ema. europa.eu/documents/product-informa tion/ajovy-epar-product-information\_ en.pdf [Accessed: 11 July 2019]

[151] Teva Pharmaceutical Industries Ltd. Ajovy™ (Fremanezumab-vfrm) Injection, for Subcutaneous Use. 2018. Available from: https://www.accessdata. fda.gov/drugsatfda\_docs/label/2018/ 761089s000lbl.pdf [Accessed: 11 July 2019]

[152] Eli Lilly and Company. Emgality (Galcanezumab-glnm) Injection, for Subcutaneous Use: US Prescribing Information. 2018. Available from: https://www.accessdata.fda.gov/drugsa tfda\_docs/label/2018/761063s000lbl. pdf [Accessed: 11 July 2019]

[153] Eli Lilly Nederland BV. Emgality (Galcanezumab) for Injection: Summary of Product Characteristics. 2018. Available from: https://www.ema.europa. eu/en/documents/product-information/ emgality-epar-product-information\_en. pdf [Accessed: 11 July 2019]

[154] Lundbeck. Vyepti (Eptinezumabjjmr): US Prescribing Information. 2020. Available from: https://www.lundbeck. com/upload/us/files/pdf/Products/ Vyepti\_PI\_US\_EN.pdf [Accessed: 05 March 2020]

[155] Dhillon S. Eptinezumab: First approval. Drugs. 2020;**80**:733-739

[156] Goldberg SW, Silberstein SD. Targeting CGRP: a new era for migraine treatment. CNS Drugs. 2015;**29**(6): 443-452

[157] Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltran E, et al. Blocking CGRP in migraine patients a review of pros and cons. The Journal of Headache and Pain. 2017;**18**(1):96

[158] Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. British Journal of Clinical Pharmacology. 2015;**80**(2):193-199

[159] Israel H, Neeb L, Reuter U. CGRP monoclonal antibodies for the preventative treatment of migraine. Current Pain and Headache Reports. 2018;**22**(5):38

[160] Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. The New England Journal of Medicine. 2017;**377**:2113-2122

[161] Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK. Galcanezumab in chronic migraine: the randomized, double-blind, placebocontrolled REGAIN study. Neurology. 2018;**91**:e1-e11

[162] Dodic DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019;**39**(9):1075-1085

[163] Sacco S, Bendtsen L, Ashina M, et al. European headache federation

guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. The Journal of Headache and Pain. 2019;**20**:6

[164] Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurology. 2017;**16**:425-434

[165] Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Silberstein SD (2015a) safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebocontrolled, phase 2b study. Lancet Neurology. 2015;**14**:1091-1100

[166] Yang M, Rendas-Baum R, Varon SF, et al. Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2010;**31**:357-367

[167] Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine PROMISE-2. Neurology. 2020;**94**(13): e1365-e1377. DOI: 10.1212/WNL.<PHONE_NUMBER>009169

[168] Kowacs F, Roesler CAP, Piovesan EJ, et al. Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arquivos de Neuro-Psiquiatria. July 2019:**77**(7): 509-520. DOI: 10.1590/0004- 282x20190078

[169] Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache. 1998;**38**(1):18-22

[170] Pellesi L, Do TP AH, et al. Dual therapy with anti-cgrp monoclonal antibodies and botulinum toxin for

migraine prevention: Is there a rationale? Headache. 2020. DOI: 10.1111/head.13843

[171] Diener HC, Dodick DW, Goadsby PJ, et al. Chronic migraine— Classification, characteristics and treatment. Nature Reviews. Neurology. 2012;**32**:423

[172] Dodick DW. Finding a fit: Strategies for chronic migraine prophylaxis. Johns Hopkins Advanced Studies in Medicine. 2006;**6**(4D)

**109**

**Chapter 6**

**Abstract**

diagnosis

**1. Introduction**

**2. Epidemiology**

Chronic Migraine in Adolescence

*Marcos Antonio da Silva Cristovam, Daniel Albiero Piélak,*

Chronic migraine (CM) is a clinically and epidemiologically important disease that generates considerable impairment to those affected by it, since there is evidence of higher incidence of depression, anxiety, and chronic pain in patients with this condition. It is characterized by the occurrence of headache for at least 8 migraine days in a month and at least 15 headache days in the same month. Despite the similarity in CM presented in adults, when in adolescents it has some particularities. Thus, the aim of this chapter was to conduct a literature review, using the databases: PubMed, SciELO, and LILACS, in addition to text books, explaining the definition, epidemiology, risk factors, diagnosis, pathophysiology, treatment, and

**Keywords:** classic migraine, migraine with auras, epidemiology, adolescence,

Chronic migraine (CM) is defined as the occurrence of headache for at least 8 migraine days in a month and at least 15 headache days in the same month [1], being much less common and more debilitating than episodic migraine. Evidence indicates that migraine is a progressive disorder [2–4], and therefore, diagnosis and early management of episodic migraine are recommended, in order to avoid its chronicity, especially in adolescents; however, there is a failure in the accuracy of the diagnosis of CM in this population [5]. Migraine in this population can be misdiagnosed as sinusitis, attempted school skipping, and cerebral neoplasia, which

CM is a common disorder in children, and its incidence in adolescents presents a considerable increase [7]. Irrespective of age, the prevalence of chronic migraine is estimated at 1.5–2% in general population. On the other hand, its prevalence is 3% (from 3 to 7 years of age), 4–11% (from 7 to 11 years of age), and 8–23% (at 11 years of age), with a mean age of onset of 7.2 years for male and 10.9 years for female [8, 9]. Migraine is the 6th most disabling disease worldwide between the ages of 10 and 14 years and the 5th between the ages of 15 and 19 years [10]. In addition to toe the line impact inflicted by pain itself, migraine generates serious consequences

*Lorena Vaz Meleiro Lopes and Luísa Manfredin Vila*

*Júlia Deitos, Júlia Natsumi Hashimoto,*

prevention of CM in adolescent population.

may culminate in unnecessary testing [6].

#### **Chapter 6**

guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. The Journal of Headache and Pain. 2019;**20**:6

*Migraine*

migraine prevention: Is there a rationale? Headache. 2020. DOI:

[171] Diener HC, Dodick DW,

[172] Dodick DW. Finding a fit: Strategies for chronic migraine prophylaxis. Johns Hopkins Advanced Studies in Medicine. 2006;**6**(4D)

Goadsby PJ, et al. Chronic migraine— Classification, characteristics and treatment. Nature Reviews. Neurology.

10.1111/head.13843

2012;**32**:423

[164] Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet

Neurology. 2017;**16**:425-434

[165] Bigal ME, Edvinsson L,

[166] Yang M, Rendas-Baum R, Varon SF, et al. Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2010;**31**:357-367

[167] Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine PROMISE-2. Neurology. 2020;**94**(13): e1365-e1377. DOI: 10.1212/WNL.

0000000000009169

282x20190078

**108**

[168] Kowacs F, Roesler CAP, Piovesan EJ, et al. Consensus of the Brazilian Headache Society on the treatment of chronic migraine. Arquivos de Neuro-Psiquiatria. July 2019:**77**(7):

509-520. DOI: 10.1590/0004-

[169] Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache. 1998;**38**(1):18-22

[170] Pellesi L, Do TP AH, et al. Dual therapy with anti-cgrp monoclonal antibodies and botulinum toxin for

Rapoport AM, Lipton RB, Spierings EL, Diener HC, et al. Silberstein SD (2015a) safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebocontrolled, phase 2b study. Lancet Neurology. 2015;**14**:1091-1100

## Chronic Migraine in Adolescence

*Marcos Antonio da Silva Cristovam, Daniel Albiero Piélak, Júlia Deitos, Júlia Natsumi Hashimoto, Lorena Vaz Meleiro Lopes and Luísa Manfredin Vila*

#### **Abstract**

Chronic migraine (CM) is a clinically and epidemiologically important disease that generates considerable impairment to those affected by it, since there is evidence of higher incidence of depression, anxiety, and chronic pain in patients with this condition. It is characterized by the occurrence of headache for at least 8 migraine days in a month and at least 15 headache days in the same month. Despite the similarity in CM presented in adults, when in adolescents it has some particularities. Thus, the aim of this chapter was to conduct a literature review, using the databases: PubMed, SciELO, and LILACS, in addition to text books, explaining the definition, epidemiology, risk factors, diagnosis, pathophysiology, treatment, and prevention of CM in adolescent population.

**Keywords:** classic migraine, migraine with auras, epidemiology, adolescence, diagnosis

#### **1. Introduction**

Chronic migraine (CM) is defined as the occurrence of headache for at least 8 migraine days in a month and at least 15 headache days in the same month [1], being much less common and more debilitating than episodic migraine. Evidence indicates that migraine is a progressive disorder [2–4], and therefore, diagnosis and early management of episodic migraine are recommended, in order to avoid its chronicity, especially in adolescents; however, there is a failure in the accuracy of the diagnosis of CM in this population [5]. Migraine in this population can be misdiagnosed as sinusitis, attempted school skipping, and cerebral neoplasia, which may culminate in unnecessary testing [6].

#### **2. Epidemiology**

CM is a common disorder in children, and its incidence in adolescents presents a considerable increase [7]. Irrespective of age, the prevalence of chronic migraine is estimated at 1.5–2% in general population. On the other hand, its prevalence is 3% (from 3 to 7 years of age), 4–11% (from 7 to 11 years of age), and 8–23% (at 11 years of age), with a mean age of onset of 7.2 years for male and 10.9 years for female [8, 9]. Migraine is the 6th most disabling disease worldwide between the ages of 10 and 14 years and the 5th between the ages of 15 and 19 years [10]. In addition to toe the line impact inflicted by pain itself, migraine generates serious consequences

in children's and adolescent's routine, since it is responsible for school absences, negatively affecting academic performance. It also has social impacts, since it hinders the child's interactions with his peers, and economic, due to the costs generated by the treatment [11]. Migraine has two-fold higher prevalence in females when compared to their peer male adolescents [12–17]. In women, the prevalence of migraine increases during adolescence, presenting a maximum prevalence at 30 years of age, decreasing sharply after menopause [12, 14, 17], since 50–60% of women report having migraine during their menstrual period [18]. In the American Migraine Prevalence and Prevention Study (AMPP), patients with CM presented with depression, anxiety, and chronic pain twice as much as patients with episodic migraine [17]. Abu-Arafeh et al., in 2010, estimated that the overall prevalence of migraine in children is 7.7% (9.7% in female and 6.0% in male), being more common in female after completing 11 years of age, in male before the age of 7, and being equal in both sexes between 7 and 11 years of age [19, 20]. In another study, WöberBingöl et al. reported general prevalence of migraine of 9.1% [21].

### **3. Risk factors**

Among the risk factors for CM, the following are included:

In addition to the factors mentioned above, others still under study may be related to the pathophysiology of CM and, therefore, represent risk factors such as traumatic brain injury, epilepsy, hemodialysis, and excessive use of symptomatic medications.

The existence of correlation between CM and traumatic brain injury was the subject of a systematic review study published by Sowell et al., in 2017, in which was sought to relate it to posttraumatic chronic headache (PTCH) in children and adolescents. In this study, it was observed that 7.6% of children with PTCH presented migraine [24], thus disclosing it to be a relatively common condition and that it should be considered.

Another factor that may be correlated with CM is epilepsy. Both migraine and epilepsy are considered neuronal hyperarousal-related diseases which can be partially prevented by antiepileptic drugs. According to the Center of Disease Control (CDC), 16.2% of adults with no history of epilepsy have severe headache or

**111**

*Chronic Migraine in Adolescence*

*DOI: http://dx.doi.org/10.5772/intechopen.90936*

without excessive use of medication [5].

**4. Diagnosis**

population [1, 5].

phobia [1].

headache [1].

migraine, while those with active epilepsy have 35.5% of prevalence [25]. Therefore, although the correlation between epilepsy and migraine has not been completely

Regarding hemodialysis in pediatric and adolescent patients with chronic kidney disease, Davidovits and Eidlitz Markus, in a study published in the International Headache Society, concluded a three-fold higher prevalence of headache among patients in hemodialysis compared to those with chronic kidney disease without this treatment, the most commonly described type of headache being migraine. Furthermore, other variables were associated with headaches, such as anemia,

Notwithstanding, excessive symptomatic medication is also described in the literature as a risk factor for CM. With this in mind, Rojo et al. made a comparison between patients with CM with and without excessive medication use (analgesics, tryptans, ergotamine, and opioids). In the study, it was observed that individuals overusing symptomatic medication had the onset of migraine at a younger age, with a longer progression time before looking for a specialist, as well as a higher percentage of preventive prior treatment (mainly antidepressants), compared to those

Even though there are differences between the clinical findings of CM in the pediatric population and other age groups, due to the scarce evidence in relation to diagnostic methods aimed specifically at these patients, the International Classification of Headache Disorders, of Headache Classification Committee of the International Headache Society (IHS), 2018, is used, the same applied to the adult

According to IHS, CM is characterized by occurrence of ≥8 days of migraine in a month and ≥15 headache days. Migraine attacks can be with and/or without aura [1]. In this case, migraine without aura is a headache lasting 4–72 h, which has at least two of the following characteristics: (1) unilateral location; (2) pulsatile character; (3) moderate to strong pain intensity; and (4) is exacerbated by routine physical activities and, during the headache, the patient has at least one of the following symptoms: (1) nausea and/or vomiting; (2) photophobia; and (3) phono-

On the other hand, migraine with aura is a headache with the same characteristics mentioned above, plus one or more symptoms of fully reversible aura, and may be visual, sensory, speech and/or language, motor, brain stem, or retinal. Furthermore, crises should have at least three of the following characteristics: (1) at least one symptom of aura gradually spreads for more than 5 min; (2) two or more aura symptoms occur in succession; (3) each individual aura symptom lasts 5–60 min; (4) at least one symptom of aura is unilateral; (5) at least one symptom of aura is positive; and (6) aura is accompanied, or followed within 60 min, by

Although the use of IHS criteria is recommended, the health professional should know the peculiarities of CM in adolescent population in order to complement the diagnosis. The characteristics of the headache tend to be more prominent in this group, since the brain is in the growth and development process. Furthermore, the duration of pain crises may be less than 1 h, contrary to the IHS criteria, which mentions a minimum duration of 2 h [1, 6, 27]. A direct relation between the patient's age and duration of crises is observed, being younger shorter the duration of the crisis [4]. An important information is that adolescents may present

elucidated yet, there are strong indications for such an interdependence.

hyperparathyroidism, and low glomerular filtration [26].

#### *Chronic Migraine in Adolescence DOI: http://dx.doi.org/10.5772/intechopen.90936*

migraine, while those with active epilepsy have 35.5% of prevalence [25]. Therefore, although the correlation between epilepsy and migraine has not been completely elucidated yet, there are strong indications for such an interdependence.

Regarding hemodialysis in pediatric and adolescent patients with chronic kidney disease, Davidovits and Eidlitz Markus, in a study published in the International Headache Society, concluded a three-fold higher prevalence of headache among patients in hemodialysis compared to those with chronic kidney disease without this treatment, the most commonly described type of headache being migraine. Furthermore, other variables were associated with headaches, such as anemia, hyperparathyroidism, and low glomerular filtration [26].

Notwithstanding, excessive symptomatic medication is also described in the literature as a risk factor for CM. With this in mind, Rojo et al. made a comparison between patients with CM with and without excessive medication use (analgesics, tryptans, ergotamine, and opioids). In the study, it was observed that individuals overusing symptomatic medication had the onset of migraine at a younger age, with a longer progression time before looking for a specialist, as well as a higher percentage of preventive prior treatment (mainly antidepressants), compared to those without excessive use of medication [5].

#### **4. Diagnosis**

*Migraine*

**3. Risk factors**

b. age group;

in children's and adolescent's routine, since it is responsible for school absences, negatively affecting academic performance. It also has social impacts, since it hinders the child's interactions with his peers, and economic, due to the costs generated by the treatment [11]. Migraine has two-fold higher prevalence in females when compared to their peer male adolescents [12–17]. In women, the prevalence of migraine increases during adolescence, presenting a maximum prevalence at 30 years of age, decreasing sharply after menopause [12, 14, 17], since 50–60% of women report having migraine during their menstrual period [18]. In the American Migraine Prevalence and Prevention Study (AMPP), patients with CM presented with depression, anxiety, and chronic pain twice as much as patients with episodic migraine [17]. Abu-Arafeh et al., in 2010, estimated that the overall prevalence of migraine in children is 7.7% (9.7% in female and 6.0% in male), being more common in female after completing 11 years of age, in male before the age of 7, and being equal in both sexes between 7 and 11 years of age [19, 20]. In another study,

WöberBingöl et al. reported general prevalence of migraine of 9.1% [21].

a.gender (female, once migraine has been associated with menorrhagia, dysmen-

d. genetic factors: family history of headache, mental disorders [5, 22, 23], anxiety, and depression [5, 23], as well as comorbidities, such as sleep disorders [5, 23] (sleep apnea syndrome and hypopnea, snoring, and insomnia [22]), obesity [23], epilepsy [24], hypertension, asthma, hypothyroidism, genitourinary disorders, musculoskeletal disorders, [22] and gastrointestinal disorders [22, 24];

e. family and environmental factors: divorce [23], socioeconomic class [5, 23],

f. other factors: pro-thrombotic factors [5] and pro-inflammatory factors [5, 23].

In addition to the factors mentioned above, others still under study may be related to the pathophysiology of CM and, therefore, represent risk factors such as traumatic brain injury, epilepsy, hemodialysis, and excessive use of symptomatic

The existence of correlation between CM and traumatic brain injury was the subject of a systematic review study published by Sowell et al., in 2017, in which was sought to relate it to posttraumatic chronic headache (PTCH) in children and adolescents. In this study, it was observed that 7.6% of children with PTCH presented migraine [24], thus disclosing it to be a relatively common condition and

Another factor that may be correlated with CM is epilepsy. Both migraine and epilepsy are considered neuronal hyperarousal-related diseases which can be partially prevented by antiepileptic drugs. According to the Center of Disease Control (CDC), 16.2% of adults with no history of epilepsy have severe headache or

Among the risk factors for CM, the following are included:

orrhoea, and endometriosis [22]);

c. ethnicity: more specifically, white;

and low level of education [5]; and

**110**

medications.

that it should be considered.

Even though there are differences between the clinical findings of CM in the pediatric population and other age groups, due to the scarce evidence in relation to diagnostic methods aimed specifically at these patients, the International Classification of Headache Disorders, of Headache Classification Committee of the International Headache Society (IHS), 2018, is used, the same applied to the adult population [1, 5].

According to IHS, CM is characterized by occurrence of ≥8 days of migraine in a month and ≥15 headache days. Migraine attacks can be with and/or without aura [1]. In this case, migraine without aura is a headache lasting 4–72 h, which has at least two of the following characteristics: (1) unilateral location; (2) pulsatile character; (3) moderate to strong pain intensity; and (4) is exacerbated by routine physical activities and, during the headache, the patient has at least one of the following symptoms: (1) nausea and/or vomiting; (2) photophobia; and (3) phonophobia [1].

On the other hand, migraine with aura is a headache with the same characteristics mentioned above, plus one or more symptoms of fully reversible aura, and may be visual, sensory, speech and/or language, motor, brain stem, or retinal. Furthermore, crises should have at least three of the following characteristics: (1) at least one symptom of aura gradually spreads for more than 5 min; (2) two or more aura symptoms occur in succession; (3) each individual aura symptom lasts 5–60 min; (4) at least one symptom of aura is unilateral; (5) at least one symptom of aura is positive; and (6) aura is accompanied, or followed within 60 min, by headache [1].

Although the use of IHS criteria is recommended, the health professional should know the peculiarities of CM in adolescent population in order to complement the diagnosis. The characteristics of the headache tend to be more prominent in this group, since the brain is in the growth and development process. Furthermore, the duration of pain crises may be less than 1 h, contrary to the IHS criteria, which mentions a minimum duration of 2 h [1, 6, 27]. A direct relation between the patient's age and duration of crises is observed, being younger shorter the duration of the crisis [4]. An important information is that adolescents may present

nonpulsatile and bilateral pain, which may induce the misdiagnosis of tensional headache [2, 6, 27].

Approximately 10% of young people with migraine present aura, from visual, sensory, speech, or language disorders, motor, or brain stem changes, manifesting themselves as scotomas, paresthesias, dysphasias, hemiplegia, ataxia, or confusion. The suspicion of other diseases of the central nervous system should be listed through fever, nuchal stiffness, altered mental status, absence of family history of migraine, occipital or positional headaches, or headaches that constantly awaken the individual during sleep [28–30].

In adolescents, it is common for patients with migraine to have comorbidities such as epilepsy and atopy. The most common atopic disorders reported concomitantly with CM are seasonal rhinitis, conjunctivitis, and asthma, with correlation with positive family history. Regarding epilepsy, it is mainly associated with migraine with aura, which corroborates the role of depression of cortical propagation. Another hypothesis is that both, migraine and epilepsy, have the influence of canalopathies on their pathophysiology [30–32].

#### **5. Pathophysiology**

The mechanisms responsible for the occurrence of CM are not yet fully understood. Thus, the existing model to explain its pathophysiology still has gaps. It is accepted that migraine occurs by complex mechanisms involving activation and sensitization of trigeminal nociceptive pathways, especially its ophythalmic division, changes of the autonomic nervous system function, descending pain modulator system dysfunction, thalamic sensitization, and central sensitization due to the excessive use of medication in the acute treatment of pain crises.

It is noteworthy that the córtex of patients with migraine is hyperexcitable and abnormally sensitive to external stimuli. Due to triggering factors, the so-called cortical spreading depression (CSD) occurs, characterized by a slow propagation wave (2–6 mm/min) of sustained neuronal depolarization, which generates a transient peak of intense activity as it progresses in the tissue, followed by a longterm neural suppression. That is, there is a period of electrochemical hyperactivity followed by cortical inactivity, which results in the release of substances in the extracelular environment (ECE), such as K<sup>+</sup> and H<sup>+</sup> ions, nitric oxide, arachidonic acid, and prostaglandins [33–35]. Such a change in the ECE may activate or sensitize trigeminal afferences. The trigeminal ganglia, once stimulated, releases neuropeptides, causing inflammation of the dura mater. Cernuda-Morollón et al. demonstrate in their studies that interictal levels of calcitonin gene-related peptide (CGRP) and intestinal vasoactive peptide (IVP) are higher in CM [36, 37]. Thus, meningeal inflammation occurs, with vasodilation and endotelial dysfunction, resulting in plasma leakage and release of more inflammatory cytokines by mast cells. Thereby, neurogenic inflammation can lead to activation and sensitization of meningeal trigeminal afferences—a phenomenon known as peripheral sensitization [38–40].

A widely spread hypothesis is that increased peripheral nociceptive processing triggers increased activity of the descending pain modulation system, resulting in increased oxidative stress and consequent nociceptive modulation, further lowering the threshold for new pain crises. However, so far studies have not shown association between gene polymorphisms associated with oxidative stress and the occurrence of CM. On the other hand, repetitive painful stimuli on the trigeminal nerve cause activation of the pain modulating descending system in several portions, including the periaqueductal gray matter, showing that during migraine attacks, the

**113**

*Chronic Migraine in Adolescence*

migraine [44–47].

allodynia [48–50].

the lack of it [33, 53].

treatment adherence [5].

**6.1 General and supportive measures**

**6. Treatment**

tial biomarker of this disease [51].

*DOI: http://dx.doi.org/10.5772/intechopen.90936*

neurons of this region show increased activity, which may lead to oxidative stress and finally dysfunction of nociceptive modulation by such system [33, 41–43].

The overuse of medications to relieve acute migraine may also lead to the chronicity of this condition, through the drug-mediated central sensitization mechanism, leading to increased susceptibility to cortical spreading depression. Central sensitization manifests clinically from increased pericranial sensitivity and

Andersen et al. demonstrated in 2016 that during pain crises serum miRNA changes occur, and in patients with CM such changes persist the same in periods without pain. This implies the possibility of serum miRNA changes as a pathogenic feature of migraine. Thus, the study suggests that serum miRNA dosage is a poten-

According to Oakley et al., there is a possibility that obesity may be involved in the pathophysiology of migraine in the pediatric population. It is hypothesized that there is an overlap of the central and peripheral neural pathways responsible for the regulation of diet and those linked to the pathogenesis of migraine [33, 52]. Peterlin et al. demonstrated that several hypothalamic peptides, proteins, and neurotransmitters involved in the mechanisms of hunger also participate in the pathophysiology of migraine, such as serotonin, orexin, and adipokines. It is possible that the release of these substances, associated with the mechanism of diet and/or obesity states, may act as a trigger or corroborate the development of migraine. There is also the possibility that lifestyle and behavioral differences influence the relationship between migraine and obesity, such as differences in diet and physical exercise, or

The treatment of chronic migraine in adolescents aims not only to reduce frequency, duration, and intensity of the headache attacks, but also to reduce the consequences of this condition on the patient's quality of life, seeing as he or she is going through a process of growth and development. It also aims to treat comorbidities and reduce the social impact of the disease, such as school absences, school underachievement, and reduced peer interactions. Thus, the treatment should be developed from a multiprofessional perspective, with the help of pediatricians, neurologists and psychiatrists, psychologists, educators, and nutritionists, among others [54].

Firstly, family members should receive detailed information about the adolescent's diagnosis and ensure that the condition is not secondary to malignant diseases, in order to transmit confidence to the patient and their parents, thus contributing to

Proper living habits are of paramount importance for treatment. However, the health professional should be careful to not excessively restrict the activities of

young people, as this may lead to difficulties in adherence [55].

Thalamic modulation of trigeminal afferences appears to be related to the development of cutaneous allodynia in migraine, as sensitized thalamic neurons process nociceptive information from cranial meninges, along with sensory information from the scalp, skin, face, body, and limbs. Furthermore, the use of drugs that act modulating trigeminal afferences on the thalamus is effective in the preventive treatment of migraine attacks, such as topiramate, sodium valproate, and CGR66 receptor antagonists, corroborating the role of this structure in the chronicity of

#### *Chronic Migraine in Adolescence DOI: http://dx.doi.org/10.5772/intechopen.90936*

*Migraine*

headache [2, 6, 27].

**5. Pathophysiology**

sensitization [38–40].

the individual during sleep [28–30].

canalopathies on their pathophysiology [30–32].

extracelular environment (ECE), such as K<sup>+</sup>

nonpulsatile and bilateral pain, which may induce the misdiagnosis of tensional

Approximately 10% of young people with migraine present aura, from visual, sensory, speech, or language disorders, motor, or brain stem changes, manifesting themselves as scotomas, paresthesias, dysphasias, hemiplegia, ataxia, or confusion. The suspicion of other diseases of the central nervous system should be listed through fever, nuchal stiffness, altered mental status, absence of family history of migraine, occipital or positional headaches, or headaches that constantly awaken

In adolescents, it is common for patients with migraine to have comorbidities such as epilepsy and atopy. The most common atopic disorders reported concomitantly with CM are seasonal rhinitis, conjunctivitis, and asthma, with correlation with positive family history. Regarding epilepsy, it is mainly associated with migraine with aura, which corroborates the role of depression of cortical propagation. Another hypothesis is that both, migraine and epilepsy, have the influence of

The mechanisms responsible for the occurrence of CM are not yet fully understood. Thus, the existing model to explain its pathophysiology still has gaps. It is accepted that migraine occurs by complex mechanisms involving activation and sensitization of trigeminal nociceptive pathways, especially its ophythalmic division, changes of the autonomic nervous system function, descending pain modulator system dysfunction, thalamic sensitization, and central sensitization due to the

It is noteworthy that the córtex of patients with migraine is hyperexcitable and abnormally sensitive to external stimuli. Due to triggering factors, the so-called cortical spreading depression (CSD) occurs, characterized by a slow propagation wave (2–6 mm/min) of sustained neuronal depolarization, which generates a transient peak of intense activity as it progresses in the tissue, followed by a longterm neural suppression. That is, there is a period of electrochemical hyperactivity followed by cortical inactivity, which results in the release of substances in the

donic acid, and prostaglandins [33–35]. Such a change in the ECE may activate or sensitize trigeminal afferences. The trigeminal ganglia, once stimulated, releases neuropeptides, causing inflammation of the dura mater. Cernuda-Morollón et al. demonstrate in their studies that interictal levels of calcitonin gene-related peptide (CGRP) and intestinal vasoactive peptide (IVP) are higher in CM [36, 37]. Thus, meningeal inflammation occurs, with vasodilation and endotelial dysfunction, resulting in plasma leakage and release of more inflammatory cytokines by mast cells. Thereby, neurogenic inflammation can lead to activation and sensitization of meningeal trigeminal afferences—a phenomenon known as peripheral

A widely spread hypothesis is that increased peripheral nociceptive processing triggers increased activity of the descending pain modulation system, resulting in increased oxidative stress and consequent nociceptive modulation, further lowering the threshold for new pain crises. However, so far studies have not shown association between gene polymorphisms associated with oxidative stress and the occurrence of CM. On the other hand, repetitive painful stimuli on the trigeminal nerve cause activation of the pain modulating descending system in several portions, including the periaqueductal gray matter, showing that during migraine attacks, the

and H<sup>+</sup>

ions, nitric oxide, arachi-

excessive use of medication in the acute treatment of pain crises.

**112**

neurons of this region show increased activity, which may lead to oxidative stress and finally dysfunction of nociceptive modulation by such system [33, 41–43].

Thalamic modulation of trigeminal afferences appears to be related to the development of cutaneous allodynia in migraine, as sensitized thalamic neurons process nociceptive information from cranial meninges, along with sensory information from the scalp, skin, face, body, and limbs. Furthermore, the use of drugs that act modulating trigeminal afferences on the thalamus is effective in the preventive treatment of migraine attacks, such as topiramate, sodium valproate, and CGR66 receptor antagonists, corroborating the role of this structure in the chronicity of migraine [44–47].

The overuse of medications to relieve acute migraine may also lead to the chronicity of this condition, through the drug-mediated central sensitization mechanism, leading to increased susceptibility to cortical spreading depression. Central sensitization manifests clinically from increased pericranial sensitivity and allodynia [48–50].

Andersen et al. demonstrated in 2016 that during pain crises serum miRNA changes occur, and in patients with CM such changes persist the same in periods without pain. This implies the possibility of serum miRNA changes as a pathogenic feature of migraine. Thus, the study suggests that serum miRNA dosage is a potential biomarker of this disease [51].

According to Oakley et al., there is a possibility that obesity may be involved in the pathophysiology of migraine in the pediatric population. It is hypothesized that there is an overlap of the central and peripheral neural pathways responsible for the regulation of diet and those linked to the pathogenesis of migraine [33, 52]. Peterlin et al. demonstrated that several hypothalamic peptides, proteins, and neurotransmitters involved in the mechanisms of hunger also participate in the pathophysiology of migraine, such as serotonin, orexin, and adipokines. It is possible that the release of these substances, associated with the mechanism of diet and/or obesity states, may act as a trigger or corroborate the development of migraine. There is also the possibility that lifestyle and behavioral differences influence the relationship between migraine and obesity, such as differences in diet and physical exercise, or the lack of it [33, 53].

#### **6. Treatment**

#### **6.1 General and supportive measures**

The treatment of chronic migraine in adolescents aims not only to reduce frequency, duration, and intensity of the headache attacks, but also to reduce the consequences of this condition on the patient's quality of life, seeing as he or she is going through a process of growth and development. It also aims to treat comorbidities and reduce the social impact of the disease, such as school absences, school underachievement, and reduced peer interactions. Thus, the treatment should be developed from a multiprofessional perspective, with the help of pediatricians, neurologists and psychiatrists, psychologists, educators, and nutritionists, among others [54].

Firstly, family members should receive detailed information about the adolescent's diagnosis and ensure that the condition is not secondary to malignant diseases, in order to transmit confidence to the patient and their parents, thus contributing to treatment adherence [5].

Proper living habits are of paramount importance for treatment. However, the health professional should be careful to not excessively restrict the activities of young people, as this may lead to difficulties in adherence [55].

Sleep disorders are important comorbidities of chronic migraine. Therefore, regular sleep habits should be advocated in order to promote restful and restorative sleep. For this, the teenager can use some techniques, such as scheduling a daily bedtime, avoid using electronic media when in bed, avoid eating 4 h before bedtime, and avoid daytime naps. Still, sleep deprivation can be a triggering factor for pain crises, corroborating the importance of a well-slept night [56, 57].

Regarding food, it is important to prioritize regular meals, with the consumption of healthy foods and adequate hydration. Caffeine and tobacco should be avoided. The performance of physical activities should be encouraged, as it not only reduces the occurrence of crises, but also is able to assist in the treatment of depression and anxiety comorbidities, when present [58, 59].

Gelfand et al. emphasize that the patient should be alerted about the negative effects of overuse of medications, as it is one of the factors responsible for the chronicity of migraine, from the central sensitization mechanism, as previously explained about the pathophysiology [60].

Kroon Van Diest et al. [61], based on a randomized study, demonstrated the importance of Cognitive Behavioral Therapy (CBT) for adherence to pharmacological treatment and institution of lifestyle changes [62]. CBT aims, through interventions guided by a psychologist, to promote the patient's active learning in order to implement skills to deal with migraine and related conditions and situations to her. Thus, during the sessions, behavioral coping skills are worked out, such as problemsolving and thought restructuring, that is, the adolescent is urged to change their ideas, beliefs, and attitudes regarding his chronic condition [62]. CBT, in combination with amitriptyline, is suggested as a first-line treatment in the context of CM in adolescents [61].

#### **6.2 Acute treatment**

Regarding acute pharmacological treatment, that is, to relieve pain crises, nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans are used [28, 63, 64]. Among NSAIDs, the most used are ibuprofen and naproxen [28]. Evers et al. demonstrated that ibuprofen is better than placebo. There is no evidence regarding the efficacy of acetaminophen in adolescents [63, 65, 66].

In the adolescent population, the following triptans are indicated: sumatriptan, rizatriptan, zolmitriptan, and almotriptan. Studies indicate that such drugs are the most effective in relieving pain during acute crises in adolescents, with no statistically significant differences between them [63]. According to Derosier et al., the combination of naproxen and sumatriptan was superior to placebo when analyzing the permanence of analgesia after 2 h, with sumatriptan + naproxen sodium 10 mg + 60 mg (29%; p = 0,003), 30 mg + 180 mg (27%; p = 0.003), and 85 mg + 500 mg (24%; p = 0.003) versus placebo (10%) [67]. Among the side effects of this class, the most common are mild fatigue, paresthesia, dizziness, and taste disorders [28, 64].

In the case of long-term migraine or migratory status, that is, disabling crisis lasting more than 72 h, hospital treatment may be required for intravenous administration of prochlorperazine with ketorolac, which Brousseau showed that 57% of patients had pain reduction in 60 min [28, 68]. Dihydroergotamine (DHE) has been shown to be well tolerated and effective in acute treatment and is generally administered in hospital setting, and an association with metoclopramide or prochlorperazine is suggested, which is able to attenuate gastrointestinal side effects [28, 69]. Ayulo et al. suggested the use of intravenous lidocaine for the treatment of migratory status in adolescents, but further evidence is needed to ensure the longterm efficacy and safety of this medication [28, 70].

**115**

*Chronic Migraine in Adolescence*

**6.3 Preventive treatment**

prevention will be presented.

6.6 days, respectively).

NSAIDs, and triptans [93].

**7. Conclusion**

economic repercussions.

contribute to the onset or that are correlated.

*DOI: http://dx.doi.org/10.5772/intechopen.90936*

Prevention of chronic migraine attacks in adolescents remains limited [71, 72]. Newly developed therapies, including drugs, biologic products, and neuromodulation devices are safe and well tolerated in adults [73–80]. Studies in the pediatric population are still being developed [81]. Therefore, the current nonpediatric

Epidemiological studies suggest that approximately 38% of migraine patients require preventive therapy, however, only 3–13% currently use it [12]. The prevention of CM currently presents concrete evidence for the following drugs: onabotulinumtoxina [82], topiramate [83, 84], and fremanezumab (TEV-48125) [85]. Other therapies, such as β-blockers and amitriptyline, are often used despite the lack of evidence, as they are not fully effective or poorly tolerated, which may culminate in low adherence rates [85]. However, a randomized study developed by Powers et at. demonstrated that amitriptyline, when combined with Cognitive Behavioral Therapy (CBT), reduces migraine disability and pain days by 1 month—adolescents receiving amitriptyline alone (group A) reduced the number of days with headache in 1 month of 6.8 days, while those who associated amitriptyline with CBT (group B) had a reduction of 11.5 days; headache disability as assessed by the Pediatric Migraine Disability Score (PedMIDAS) decreased by 52.7 points in group B versus 38.6 points in group A [62]. Currently, new forms of prevention have been proposed, based on the understanding of the pathophysiology of the disease. The calcitonin gene-related peptide (CGRP) has increased plasma concentration during a migraine attack [86–88]. Therefore, a human monoclonal antibody against the receptor of CGRP, named Galcanezumab, which was effective in preventing migraine when given at a dose of 150 mg twice a month, was developed in a study by Skljarevski et al. [89]. Treatment with self-administered injections of subcutaneous galcanezumab [90], subcutaneous fremanezumab [91], and enerumab [92] was associated with a reduction in the number of monthly days of migraine (5.6–6.5 days, 1.3–1.5 days, and

Recent studies indicate that nonpharmacological strategies are effective in preventing CM, reducing the activation of peripheral nociceptive terminations. This can be accomplished by manipulation technique, increasing the range of motion and reducing the stiffness of the cervicothoracic spine. In the study by Gandolfi et al., patients undergoing this treatment had lower consumption of analgesics,

Guilbot et al. showed that *Tanacetum parthenium* L., magnesium, and coenzyme Q10, administered prophylactically for 3 months significantly reduced the number of monthly migraine days (4.9 ± 2.6 days) [94]. Silberstein et al. proposed the prevention of CM with noninvasive vagal stimulation, which presented better results in patients who underwent longer treatment times (6 months, in the study) [95].

CM in adolescents is a disease of clinical and epidemiological importance, since it can affect approximately a quarter of the pediatric population with an average of 11 years of age, being considered debilitating due to psychological, social, and

This disorder has intrinsic and nonmodifiable (genetic and comorbidities) risk factors, as well as modifiable risk factors, such as behavioral and socioenvironmental variables, in addition to several other elements still under study that may

#### **6.3 Preventive treatment**

*Migraine*

Sleep disorders are important comorbidities of chronic migraine. Therefore, regular sleep habits should be advocated in order to promote restful and restorative sleep. For this, the teenager can use some techniques, such as scheduling a daily bedtime, avoid using electronic media when in bed, avoid eating 4 h before bedtime, and avoid daytime naps. Still, sleep deprivation can be a triggering factor for

Regarding food, it is important to prioritize regular meals, with the consumption of healthy foods and adequate hydration. Caffeine and tobacco should be avoided. The performance of physical activities should be encouraged, as it not only reduces the occurrence of crises, but also is able to assist in the treatment of depres-

Gelfand et al. emphasize that the patient should be alerted about the negative effects of overuse of medications, as it is one of the factors responsible for the chronicity of migraine, from the central sensitization mechanism, as previously

Kroon Van Diest et al. [61], based on a randomized study, demonstrated the importance of Cognitive Behavioral Therapy (CBT) for adherence to pharmacological treatment and institution of lifestyle changes [62]. CBT aims, through interventions guided by a psychologist, to promote the patient's active learning in order to implement skills to deal with migraine and related conditions and situations to her. Thus, during the sessions, behavioral coping skills are worked out, such as problemsolving and thought restructuring, that is, the adolescent is urged to change their ideas, beliefs, and attitudes regarding his chronic condition [62]. CBT, in combination with amitriptyline, is suggested as a first-line treatment in the context of CM in

Regarding acute pharmacological treatment, that is, to relieve pain crises, nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans are used [28, 63, 64]. Among NSAIDs, the most used are ibuprofen and naproxen [28]. Evers et al. demonstrated that ibuprofen is better than placebo. There is no evidence regarding the efficacy of

In the adolescent population, the following triptans are indicated: sumatriptan, rizatriptan, zolmitriptan, and almotriptan. Studies indicate that such drugs are the most effective in relieving pain during acute crises in adolescents, with no statistically significant differences between them [63]. According to Derosier et al., the combination of naproxen and sumatriptan was superior to placebo when analyzing the permanence of analgesia after 2 h, with sumatriptan + naproxen sodium 10 mg + 60 mg (29%; p = 0,003), 30 mg + 180 mg (27%; p = 0.003), and 85 mg + 500 mg (24%; p = 0.003) versus placebo (10%) [67]. Among the side effects of this class, the most common are mild fatigue, paresthesia, dizziness, and

In the case of long-term migraine or migratory status, that is, disabling crisis lasting more than 72 h, hospital treatment may be required for intravenous administration of prochlorperazine with ketorolac, which Brousseau showed that 57% of patients had pain reduction in 60 min [28, 68]. Dihydroergotamine (DHE) has been shown to be well tolerated and effective in acute treatment and is generally administered in hospital setting, and an association with metoclopramide or prochlorperazine is suggested, which is able to attenuate gastrointestinal side effects [28, 69]. Ayulo et al. suggested the use of intravenous lidocaine for the treatment of migratory status in adolescents, but further evidence is needed to ensure the long-

pain crises, corroborating the importance of a well-slept night [56, 57].

sion and anxiety comorbidities, when present [58, 59].

explained about the pathophysiology [60].

acetaminophen in adolescents [63, 65, 66].

term efficacy and safety of this medication [28, 70].

adolescents [61].

**6.2 Acute treatment**

taste disorders [28, 64].

**114**

Prevention of chronic migraine attacks in adolescents remains limited [71, 72]. Newly developed therapies, including drugs, biologic products, and neuromodulation devices are safe and well tolerated in adults [73–80]. Studies in the pediatric population are still being developed [81]. Therefore, the current nonpediatric prevention will be presented.

Epidemiological studies suggest that approximately 38% of migraine patients require preventive therapy, however, only 3–13% currently use it [12]. The prevention of CM currently presents concrete evidence for the following drugs: onabotulinumtoxina [82], topiramate [83, 84], and fremanezumab (TEV-48125) [85]. Other therapies, such as β-blockers and amitriptyline, are often used despite the lack of evidence, as they are not fully effective or poorly tolerated, which may culminate in low adherence rates [85]. However, a randomized study developed by Powers et at. demonstrated that amitriptyline, when combined with Cognitive Behavioral Therapy (CBT), reduces migraine disability and pain days by 1 month—adolescents receiving amitriptyline alone (group A) reduced the number of days with headache in 1 month of 6.8 days, while those who associated amitriptyline with CBT (group B) had a reduction of 11.5 days; headache disability as assessed by the Pediatric Migraine Disability Score (PedMIDAS) decreased by 52.7 points in group B versus 38.6 points in group A [62].

Currently, new forms of prevention have been proposed, based on the understanding of the pathophysiology of the disease. The calcitonin gene-related peptide (CGRP) has increased plasma concentration during a migraine attack [86–88]. Therefore, a human monoclonal antibody against the receptor of CGRP, named Galcanezumab, which was effective in preventing migraine when given at a dose of 150 mg twice a month, was developed in a study by Skljarevski et al. [89]. Treatment with self-administered injections of subcutaneous galcanezumab [90], subcutaneous fremanezumab [91], and enerumab [92] was associated with a reduction in the number of monthly days of migraine (5.6–6.5 days, 1.3–1.5 days, and 6.6 days, respectively).

Recent studies indicate that nonpharmacological strategies are effective in preventing CM, reducing the activation of peripheral nociceptive terminations. This can be accomplished by manipulation technique, increasing the range of motion and reducing the stiffness of the cervicothoracic spine. In the study by Gandolfi et al., patients undergoing this treatment had lower consumption of analgesics, NSAIDs, and triptans [93].

Guilbot et al. showed that *Tanacetum parthenium* L., magnesium, and coenzyme Q10, administered prophylactically for 3 months significantly reduced the number of monthly migraine days (4.9 ± 2.6 days) [94]. Silberstein et al. proposed the prevention of CM with noninvasive vagal stimulation, which presented better results in patients who underwent longer treatment times (6 months, in the study) [95].

#### **7. Conclusion**

CM in adolescents is a disease of clinical and epidemiological importance, since it can affect approximately a quarter of the pediatric population with an average of 11 years of age, being considered debilitating due to psychological, social, and economic repercussions.

This disorder has intrinsic and nonmodifiable (genetic and comorbidities) risk factors, as well as modifiable risk factors, such as behavioral and socioenvironmental variables, in addition to several other elements still under study that may contribute to the onset or that are correlated.

The diagnosis of migraine is made clinically according to the ICHD-3 criteria, taking into account the particularities of the adolescent population.

Pathophysiology, as well as risk factors and prevention, are still not completely elucidated items in CM. However, it is generally agreed that migraine occurs from complex mechanisms involving activation and sensitization of trigeminal nociceptives pathways, alteration of autonomic nervous system function, pain modulating descending system dysfunction, thalamic sensitization and further central sensitization due to the overuse of medicines in the acute treatment of pain crises.

Treatment, in turn, is multiprofessional and supported by both pharmacological and nonpharmacological measures. Nonpharmacological measures include guidance to parents and family members about the chronic condition, as well as sleep hygiene and adoption of good eating habits by the patient. In the case of drug measures, NSAIDs and triptans are the first option and, in case of migraine status, prochlorperazine associated with intravenous ketorolac added to recent evidence suggesting the use of intravenous lidocaine.

Finally, studies are still needed to fill the gaps present for the complete understanding of this complex and debilitating entity that is chronic migraine. Through a better understanding of the pathophysiological mechanisms responsible for the development of CM, as well as its risk factors, it will be possible to develop more effective prevention and treatment methods in adolescents.

#### **Author details**

Marcos Antonio da Silva Cristovam1 \*, Daniel Albiero Piélak<sup>2</sup> , Júlia Deitos3 , Júlia Natsumi Hashimoto3 , Lorena Vaz Meleiro Lopes3 and Luísa Manfredin Vila<sup>3</sup>

1 Clinical Pediatrics of Western Paraná State University, Cascavel, PR, Brazil

2 Western Paraná Universitary Hospital of Western Paraná State University, Cascavel, PR, Brazil

3 Western Paraná State University School of Medicine, Cascavel, PR, Brazil

\*Address all correspondence to<EMAIL_ADDRESS>
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**117**

*Chronic Migraine in Adolescence*

**References**

2018;**38**(1):1-211

2015;**55**(2):103-122

2004;**291**(4):493-494

2005;**45**(1):3-13

s11916-016-0538-z

2010;**30**:1065-1072

1992;**267**:64-69

*DOI: http://dx.doi.org/10.5772/intechopen.90936*

[1] Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. Cephalalgia.

Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet.

[11] Arruda MA, Bigal ME. Migraine

preadolescent children: Association with school performance. Neurology.

Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology.

 Age-dependent prevalence and clinical features of migraine. Neurology.

[14] Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;

[15] Ando N, Fujimoto S, Ishikawa T, et al. Prevalence and features of migraine in Japanese junior high school students aged 12-15 yr. Brain & Development. 2007;**29**:482-485

[16] Zencir M, Ergin H, Sahiner T, et al. Epidemiology and symptomatology of migraine among school children: Denizli urban area in Turkey. Headache.

[17] Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American migraine study

II. Headache. 2001;**41**:646-657

2016;**388**:1545-1602

2012;**79**:1881-1888

2007;**68**:343-349

2006;**67**:246-251

**23**:519-527

2004;**44**:780-785

and migraine subtypes in

[12] Lipton RB, Bigal ME,

[2] Lipton RB, Silberstein SD. Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention. Headache.

[3] Lipton RB, Pan J. Is migraine a progressive brain disease? Journal of the American Medical Association.

[4] Lipton RB, Bigal ME. Migraine: Epidemiology, impact, and risk factors for progression. Headache.

[5] Özge A, Yalın OÖ. Chronic

2016;**20**(2):1-7. DOI: 10.1007/

migraine in children and adolescents. Current Pain and Headache Reports.

[6] Gelfand AA. Migraine in young children. Developmental Medicine and Child Neurology. 2015;**57**(6):503

[7] Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: A life-span study. Cephalalgia.

[8] Stewart WF, Linet MS, Celentano DD, Van Natta M, Siegler D. Age and sexspecific incidence rates of migraine with and without visual aura. American Journal of Epidemiology. 1991;**34**:1111-1120

[9] Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Journal of the American Medical Association.

[10] GBD 2015 Disease and Injury

Incidence and Prevalence

### **References**

*Migraine*

The diagnosis of migraine is made clinically according to the ICHD-3 criteria,

Pathophysiology, as well as risk factors and prevention, are still not completely elucidated items in CM. However, it is generally agreed that migraine occurs from complex mechanisms involving activation and sensitization of trigeminal nociceptives pathways, alteration of autonomic nervous system function, pain modulating descending system dysfunction, thalamic sensitization and further central sensitization due to the overuse of medicines in the acute treatment of pain crises.

Treatment, in turn, is multiprofessional and supported by both pharmacological and nonpharmacological measures. Nonpharmacological measures include guidance to parents and family members about the chronic condition, as well as sleep hygiene and adoption of good eating habits by the patient. In the case of drug measures, NSAIDs and triptans are the first option and, in case of migraine status, prochlorperazine associated with intravenous ketorolac added to recent evidence

Finally, studies are still needed to fill the gaps present for the complete understanding of this complex and debilitating entity that is chronic migraine. Through a better understanding of the pathophysiological mechanisms responsible for the development of CM, as well as its risk factors, it will be possible to develop more

\*, Daniel Albiero Piélak<sup>2</sup>

, Lorena Vaz Meleiro Lopes3

1 Clinical Pediatrics of Western Paraná State University, Cascavel, PR, Brazil

2 Western Paraná Universitary Hospital of Western Paraná State University,

3 Western Paraná State University School of Medicine, Cascavel, PR, Brazil

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium,

\*Address all correspondence to<EMAIL_ADDRESS>
, Júlia Deitos3

and Luísa Manfredin Vila<sup>3</sup>

,

taking into account the particularities of the adolescent population.

suggesting the use of intravenous lidocaine.

effective prevention and treatment methods in adolescents.

**116**

**Author details**

Marcos Antonio da Silva Cristovam1

provided the original work is properly cited.

Júlia Natsumi Hashimoto3

Cascavel, PR, Brazil

[1] Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders. Cephalalgia. 2018;**38**(1):1-211

[2] Lipton RB, Silberstein SD. Episodic and chronic migraine headache: Breaking down barriers to optimal treatment and prevention. Headache. 2015;**55**(2):103-122

[3] Lipton RB, Pan J. Is migraine a progressive brain disease? Journal of the American Medical Association. 2004;**291**(4):493-494

[4] Lipton RB, Bigal ME. Migraine: Epidemiology, impact, and risk factors for progression. Headache. 2005;**45**(1):3-13

[5] Özge A, Yalın OÖ. Chronic migraine in children and adolescents. Current Pain and Headache Reports. 2016;**20**(2):1-7. DOI: 10.1007/ s11916-016-0538-z

[6] Gelfand AA. Migraine in young children. Developmental Medicine and Child Neurology. 2015;**57**(6):503

[7] Victor TW, Hu X, Campbell JC, Buse DC, Lipton RB. Migraine prevalence by age and sex in the United States: A life-span study. Cephalalgia. 2010;**30**:1065-1072

[8] Stewart WF, Linet MS, Celentano DD, Van Natta M, Siegler D. Age and sexspecific incidence rates of migraine with and without visual aura. American Journal of Epidemiology. 1991;**34**:1111-1120

[9] Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Journal of the American Medical Association. 1992;**267**:64-69

[10] GBD 2015 Disease and Injury Incidence and Prevalence

Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;**388**:1545-1602

[11] Arruda MA, Bigal ME. Migraine and migraine subtypes in preadolescent children: Association with school performance. Neurology. 2012;**79**:1881-1888

[12] Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy.  Age-dependent prevalence and clinical features of migraine. Neurology. 2006;**67**:246-251

[14] Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003; **23**:519-527

[15] Ando N, Fujimoto S, Ishikawa T, et al. Prevalence and features of migraine in Japanese junior high school students aged 12-15 yr. Brain & Development. 2007;**29**:482-485

[16] Zencir M, Ergin H, Sahiner T, et al. Epidemiology and symptomatology of migraine among school children: Denizli urban area in Turkey. Headache. 2004;**44**:780-785

[17] Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American migraine study II. Headache. 2001;**41**:646-657

[18] Granella F, Sances G, Zanferrari C, Costa A, Martignoni E, Manzoni GC. Migraine without aura and reproductive life events: A clinical epidemiological study in 1300 women. Headache. 1993;**33**:385-389

[19] Abu-Arafeh I, Razak S, Sivaraman B, et al. Prevalence of headache and migraine in children and adolescents: A systematic review of population-based studies. Developmental Medicine and Child Neurology. 2010;**52**(12):1088-1097

[20] Mehta S. Study of various social and demographic variables associated with primary headache disorders in 500 school-going children of central India. Journal of Pediatric Neurosciences. 2015;**10**(1):13

[21] Wöber-Bingöl Ç. Epidemiology of migraine and headache in children and adolescents. Current Pain and Headache Reports. 2013;**17**(6):1-11

[22] Spierings ELH, Padamsee A. Menstrual-cycle and menstruation disorders in episodic vs chronic migraine: An exploratory study. Pain Medicine. 2015;**16**(7):1426-1432. DOI: 10.1111/pme.12788

[23] Rojo E, Pedraza MI, Muñoz I, Mulero P, Ruiz M, de la Cruz C, et al. Diferencias entre migraña crónica con y sin uso excesivo de medicación: Experiencia en una serie hospitalaria de 434 pacientes. Neurología. 2015;**30**(3):153-157. DOI: 10.1016/j. nrl.2013.12.003

[24] Sowell MK, Youssef PE. The comorbidity of migraine and epilepsy in children and adolescents. Seminars in Pediatric Neurology. 2016;**23**(1):8391. DOI: 10.1016/j.spen.2016.01.012

[25] Shaw L, Morozova M, Abu-Arafeh I. Chronic post-traumatic headache in children and adolescents: Systematic review of prevalence and headache

features. Pain Management. 2018;**8**(1):57-64. DOI: 10.2217/ pmt-2017-0019

[26] Davidovits M, Eidlitz Markus T. Headache in pediatric and adolescent patients with chronic kidney disease, with and without hemodialysis: A comparative cohort study. Cephalalgia. 2017;**38**(5):883-891. DOI: 10.1177/0333102417719235

[27] Mariani R, Torriero R, Capuano A, et al. Clinical characteristics of primary headaches in children younger than 6 years. Cephalalgia. 2015;**35**:7-7

[28] Slater SK, Powers SW, O'Brien HL. Migraine in children. Current Opinion in Pediatrics. 2018;**1**:775-778. DOI:10.1097/ mop.0000000000000694

[29] Lewis DW, Ashwal S, Dahl G, et al. Practice parameter: Evaluation of children and adolescents with recurrent headaches: Report of the quality standards Subcommittee of the American Academy of neurology and the practice Committee of the Child Neurology Society. Neurology. 2002;**59**:490-498

[30] Newton RW. Childhood headache. Archives of Disease in Childhood. Education and Practice Edition. 2008;**93**:105

[31] Özge A, Öksüz N, Ayta S, et al. Atopic disorders are more common in childhood migraine and correlated headache phenotype. Pediatrics International. 2014;**56**(6):868-872